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1. Introduction
Glial tumors, within neuroepitelial-derived lesions, are the most common intra-assial neo‐
plastic histotypes. Gliomas account for about 45% of all primary central nervous system
(CNS) tumors and 77% of all malignant primary CNS tumors. Gliomas can originate from
neural stem cells, progenitor cells, or from de-differentiated mature neural cells transformed
into cancer stem cells. Although brain tumors constitute only a small proportion of overall
human malignancies, they carry high rates of morbidity and mortality. Mortality is still close
to 100% and the average survival of patients with glioblastoma multiforme (GBM) is less
than 1 year when classical treatment is used. Recent progresses in multimodal treatment has
led to only a slight increase in average survival up to 15-18 months [1]. The effectiveness of
the actual chemotherapeutic approach and multimodal targeted therapies remains modest
in gliomas.
Gliomas are divided into different subtypes based on cell line from which they originate.
Gliomas include astrocytomas, glioblastomas, oligodendrogliomas, ependymomas and oth‐
er histological subtypes. The most common gliomas are astrocytomas, oligodendrogliomas
and ependymomas. Since 1993, the 4-level grading system proposed by the World Health
Organization (WHO), was the most widely accepted and widespread. It is based on histo‐
logic features: nuclear atypia, presence of mitoses, endothelial proliferation. Grade I gliomas
are benign with a slow proliferation rate and include pylocitic astrocytoma most common in
pediatric age. Grade II gliomas are characterized by a high degree of cellular differentiation
and grow diffusely into the normal brain parenchyma and are prone to malignant progres‐
sion. They include astrocytoma, oligodendroglioma and oligoastrocytoma. Grade III lesions
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include anaplastic astrocytoma, anaplastic oligoastrocytoma and anaplastic oligodendro‐
glioma. These tumors show a higher cellular density and a notable presence of atypia and
mitotic cells. Grade IV tumors are the most malignant and also the most frequent gliomas
and include glioblastoma and gliosarcoma. These tumors presented microvascular prolifera‐
tions and pseudopalisading necrosis.
Conventional brain tumor treatments include surgery, radiation therapy and chemotherapy.
Surgical treatment is invasive but represents the first approach for the vast majority of brain
tumors due to difficulties arising in early stage detection. However, gross total removal is
not always achievable in relation to the location of the tumor, to preserve vital nervous or
vascular structures. Aggressive treatment modalities have extended the median survival
from 4 months to 1 year, but the survival is often associated with significant impairment in
the quality of life. Radiation therapy and chemotherapy are non-invasive options often used
as adjuvant therapy, but may also be effective for curing early-stage tumors. Radiotherapy
seems to be related only to a prolonged progression-free survival, with better control of seiz‐
ures, but with no substantial differences in overall survival. Besides, patients treated with
radiotherapy, have high risk to develop some complications such as post radiation leukoen‐
cephalopathy, that is characterized by dementia, gait disturbance, incontinence, deficit in at‐
tention and executive functions. In patients with recurrent GBM, the 6-months progression-
free survival is only 21% after treatment with temozolomide [2]. The effectiveness of
systemic chemotherapy is limited by toxic effects on healthy cells, generally resulting in
morbidity or mortality of the patient. Moreover, the presence of the blood-brain barrier
(BBB) limits the passage of a wide variety of anticancer agents. The high incidence of recur‐
rence and poor prognosis of malignant gliomas compel the development of more powerful
anti-cancer treatments. Action of alkylating agents, one of the most common class of chemo‐
therapeutic drugs employed, is limited by activation of methylguanine-methyltransferase.
The compromise of the quality of remaining life as well as the limited success of current
treatment options in shrinking tumors, raise increasing concerns about the adverse effects of
cancer treatment on brain function.
Glioma cell invasion into normal tissue is thought to be a multi-factorial process, consisting
of cell interactions with extracellular matrix (ECM) and with adjacent cells, as well as accom‐
panying biochemical processes supportive of active cell movement. Tumor cell invasion re‐
quires four distinct steps: (1) detachment of invading cells from the primary tumor mass, (2)
adhesion to ECM, (3) degradation of ECM, and (4) cell motility and contractility. However,
growth of tumors necessitates, also, the recruitment of a new blood supply. Angiogenesis,
represent a key event in the progression of malignant gliomas. Tumor angiogenesis involves
multiple cellular processes including endothelial cell proliferation, migration, reorganization
of ECM and tube formation.
The advent of molecular studies allowed a new evaluation of the biology of gliomas with, a
level of precision that promises interesting advances toward the development of specific
and effective therapies. The introduction of molecularly targeted agents is one of the most
significant advances in cancer therapy in recent years. Targeted therapies block activation of
oncogenic pathways, either at the ligand-receptor interaction level or by inhibiting down‐
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stream signal transduction pathways, thereby inhibiting growth and progression of cancer.
Because of their specificity, targeted therapies should theoretically have better efficacy and
safety profiles than systemic cytotoxic chemotherapy or radiotherapy.
In  this  chapter  we  evaluated  the  invasion  and  angiogenesis  in  the  glioma  progression.
Moreover, new pharmacological agents on the basis of the more recent literature will be
evaluated.
2. Gliomas
Approximately 50% of primary brain tumors are gliomas,  arising from astrocytes,  oligo‐
dendrocytes, or their precursors and ependymal cells. Gliomas are classified from I to IV
according  to  the  WHO  malignancy  scale.  Gliomas  are  divided  into  different  subtypes
based  on  cell  line  from  which  they  originate.  The  WHO  classification  of  CNS  tumors,
now in its fourth edition, is the universal standard for classifying and grading brain neo‐
plasms. Analysis of tumour differentiation, cellularity, cytonuclear atypia, mitotic activity,
microvascular proliferation, and necrosis further enables grading of the tumour as grade
2 (diffuse infiltrating low-grade gliomas), 3 (anaplastic gliomas), or 4 (glioblastomas) with
increasing  aggressiveness.  Unfortunately,  WHO morphological  classification  is  based on
subjective criteria, lacks reproducibility, and remains imperfect in its ability to predict in‐
dividual  outcomes.  The most  recent  WHO classification introduced a number of  signifi‐
cant  changes  that  include  both  additions  and  redefinitions  or  clarifications  of  existing
entities.  Three new tumor types were added to  the glioma section.  The first  of  these is
angiocentric  glioma.  Angiocentric  gliomas are slowly growing solid hemispheric  tumors
of children and young adults. They are strongly epileptogenic, with 95% of patients pre‐
senting  with  intractable  seizures.  These  tumors  are  characterized histologically  by  elon‐
gated  bipolar  glial  tumor  cells  and  by  their  striking  perivascular  growth  pattern.
Angiocentric  gliomas  have  a  low  proliferative  potential  (MIB-1  between  1%  -  5%)  and
have been designated as WHO grade I  neoplasms. The second, pilomyxoid astrocytoma
(PMA),  is  now formally  considered as  a  distinct  more  aggressive  variant  of  PA.  PMAs
typically occur at an earlier mean age and are associated with more aggressive behavior
than Pas (pilocytic astrocytomas). PMAs are composed of bipolar (piloid or hairlike) cells
that  lie  within  a  distinct  myxoid  background  matrix.  PMAs  are  currently  considered
WHO grade II neoplasms. Atypical choroid plexus papilloma (CPP) is the third new tu‐
mor.  Cellular  atypia and increased mitotic  activity are reflected in more aggressive bio‐
logic behavior, with earlier metastases and higher recurrence rates than CPP. An aCPP is
designated as a WHO grade II neoplasm. The 2007 WHO version recognized, also, papil‐
lary  glioneuronal  tumor  (PGNT),  rosette-forming  glioneuronal  tumor  (RGNT)  of  the
fourth ventricle, and the extraventricular form of neurocytoma. PGNT is a rare relatively
well-circumscribed  clinically  indolent  tumor  that  is  exclusively  found  in  the  cerebral
hemispheres.  PGNTs  are  biphasic  tumors,  with  both  astrocytic  and  neuronal  elements.
The histologic hallmark of  PGNT is  the presence of  hyalinized vascular pseudopapillae.
Although PGNT was not  formally assigned a WHO grade in the 2007 revision,  this  tu‐
Gliomas Biology: Angiogenesis and Invasion
http://dx.doi.org/10.5772/53487
39
mor generally behaves in a benign grade I fashion. RGNTs are rare slow-growing tumors
of  young  and  middle-aged  adults.  RGNTs  contain  both  neurocytic  and  astrocytic  ele‐
ments.  Their  histologic  hallmark  is  the  formation  of  neurocytic  perivascular  pseudoro‐
settes.  RGNTs  are  designated  as  WHO  grade  I  neoplasms.  The  term  “central
neurocytoma” describes a neuronal tumor with preferential location in the lateral ventri‐
cle  body.  These  tumors  comprise  fibrillary  areas  mimicking neuropil  plus  collections  of
uniform round cells that have immunohistochemical and ultrastructural evidence of neu‐
ronal differentiation. A low proliferation rate is typical. Similar neoplasms have been re‐
ported outside the ventricular system, and the WHO 2007 designated the term “EVNCT”
(extraventricular  neurocytoma)  for  these  uncommon  tumors.  Because  the  only  distin‐
guishing  feature  is  location  EVNCTs  are  included  in  the  same  histopathologic  code  as
central  neurocytoma.  Both  central  and  extraventricular  neurocytomas  are  designated  as
WHO  grade  II  neoplasms.  Two  new  tumors  of  the  pineal  region  were  codified  in  the
WHO 2007 classification, papillary tumor of the pineal region (PTPR) and pineal paren‐
chymal tumor of intermediate differentiation (PPTID). PTPR is a rare neuroepithelial  tu‐
mor that  arises  from the  subcommissural  organ and exhibits  ependymal  differentiation.
Macroscopically, PTPRs are indistinguishable from pineocytomas. Microscopically, the tu‐
mors  are  easily  distinguished.  PTPRs  show  papillary  architecture  with  pseudostratified
columnar  epithelium.  Ultrastructural  features  suggesting  ependymal  differentiation  are
present.  Immunohistochemistry is  positive for cytokeratins.  While grading of PTPRs has
yet  to  be  defined,  most  neuropathologists  consider  these  as  WHO  grade  II  or  III  neo‐
plasms. PPTID is a newly recognized tumor intermediate in malignancy between pineo‐
cytoma and pineoblastoma. Mild-to-moderate nuclear atypia and low-to-moderate mitotic
activity  result  in  either  WHO  grade  II  or  III.  PPTIDs  have  a  much  more  aggressive
course than pineocytomas and may warrant adjuvant therapy. PPTIDs are more common
than  previously  recognized,  accounting  for  up  to  20%  of  all  pineal  parenchymal  neo‐
plasms.  Recent  reports  emphasize  their  large  size  and  focal  invasion  of  adjacent  struc‐
tures as features that distinguish them from pineocytoma [3].
According to  WHO low grade  gliomas  include  diffuse  astrocytomas  (fibrillar,  gemistio‐
cytic,  protoplasmatic,  mixed),  grade II  oligodendrogliomas and oligoastrocytomas.  Diag‐
nosis  of  anaplastic  glioma  is  based  on  the  presence  of  mitotic  activity,  while  vascular
proliferation and necrosis are typical features of GBM. The definition of low grade glio‐
ma does not refer perhaps to I grade astrocytomas, that differ from other gliomas in rela‐
tion to their  biological  behaviour,  prognosis and genetic  profile [4].  Low grade gliomas,
tend  perhaps  to  dedifferentiate:  a  global  therapeutic  approach,  related  to  gross  total  (>
90%) surgical removal, radiotherapy e chemiotherapy with temozolamide, leads only to a
slight  prolongation of  overall  survival,  calculated from 3  to  7  years  [5].  This  variability
depends from various factors:  age at  diagnosis,  tumor volume, tumor crossing the mid‐
line,  neurological  deficits  before treatment and tumor’s histology [6].  Anyway, mortality
is  near  to  100% and only 35% of  patients  with glioblastoma multiforme have a median
survival of one year or more.
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2.1. Genetics of malignant gliomas
Cancers originate as the result of hereditary or somatic alterations in genes that control criti‐
cal biological processes. The accumulation of such genetic damage over time permits the
survival and progressive transformation of abnormal cell populations that eventually lead
to the formation of a tumor. Consistent with their high malignant potential, gliomas exhibit
a vast array of well-documented genetic changes that likely contribute to their phenotype.
Gliomagenesis is characterized by several biological events, such as activated growth factor
receptor signaling pathways, downregulation of many apoptotic mechanisms and unbal‐
ance among proangiogenic and antiangiogenic factors. Several growth factor receptors, such
epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDRGF),
C-Kit, vascular endhotelial growth factor receptor (VEGFR) and others growth factors recep‐
tors, are overexpressed, amplified and/or mutated in gliomas. Features of the glioma cells
are the loss of tumor suppressor genes, which are critical for the cell growth, differentiation
and function.
The TP53 tumor suppressor gene was identified as the main driver of chromosome 17 altera‐
tions in glioblastoma, and further studies indicated that p53 plays a critical role in monitor‐
ing the genome for DNA damage and can control cell cycle arrest to permit DNA repair or
can trigger apoptosis to eliminate the damaged cell [7]. It acts as a transcriptional activator
and it repress the transcription of other genes, such as IL-6, c-fos, c-jun and other oncogenes.
The levels of p53 increase in G1 and S phases of the cell cycle. Cells transfected with the nor‐
mal gene p53 block their growth in G1, suppressing the passage S-phase. The expression of
the p53 gene cause apoptosis (programmed cell death). The effects of its mutation are the
loss of cell cycle regulation, through the inactivation of p16ink-4a, the super expression of cy‐
cline dependent kinase 4 Cdk4 and Cdk6 and of ubiquitin ligase Mdm2 and Mdm4. A simi‐
lar mechanism is created after mutation of retinoblastoma (Rb), a tumor suppressor gene.
Probably, TP53 is a gene responsible for the progression from low-grade to high-grade glio‐
mas, but its mutation is an early event. Many glioma cell lines expressing p53 mutations.
The mutated form of p53 has a crucial role in the regulation of neovascularization. It induces
increased levels of VEGF and FGFβ through an activation of the transcription of the corre‐
sponding genes. The deletion of NFKBIA (encoding nuclear factor of κ-light polypeptide
gene enhancer in B-cells inhibitor-α), an inhibitor of the EGFR-signaling pathway, promotes
tumorigenesis in glioblastomas that do not have alterations of EGFR. Bredel et al. analyzed
790 human GBMs for deletions, mutations, or expression of NFKBIA and EGFR. they stud‐
ied the tumor-suppressor activity of NFKBIA in tumor-cell culture and compared the molec‐
ular results with the outcome of GBM in 570 affected persons. NFKBIA is often deleted but
not mutated in GBM [8].
Epidermal growth factor receptor mutations include amplifications, point mutations and de‐
letions, with the most common alteration being the variant III deletion of the extracellular
domain (EGFR-vIII mutant) [9]. Platelet-derived growth factor receptor and its ligands
PDGF-A and PDGF-B are also commonly over-expressed in some glioma cells, raising the
possibility of autocrine or paracrine activation [10]. Other RTK genes, such as ERBB2, anoth‐
er member of the EGF receptor family, and MET, which encodes the hepatocyte growth fac‐
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tor receptor, have also been found to be mutated in GBMs [9]. RTKs mediate cell growth and
proliferation via downstream effectors such as Ras and phosphatidylinositide-3-kinase
(PI3K). Activity of these proteins is tightly regulated, especially by the tumor suppressors
Nf1 and Pten. The PI3K pathway is another essential survival pathway for a variety of can‐
cer cells. The tumor suppressor Pten (phosphatase and tensin homologue on chromosome
10) negatively regulates the PI3K pathway by dephosphorylating phosphatidylinositol-3,4,5-
triphosphate (PIP3) back to phosphatidylinositol-4,5-biphosphate (PIP2) [11]. Mutations in
PTEN frequently involve the phosphatase domain, and mutations in PI3K typically involve
the catalytic (p110α) and regulatory (p85α) domains.
Classically, GBM has been described as result endpoint from two main gliomagenesis path‐
ways [12-13]. Primary GBM shows amplification of the EGFR, deletion or mutation of homo‐
zygous cyclin-dependent kinase (CDK) inhibitor p16INK4A/(CDKN2A), alterations in
tumor-suppressor PTEN on chromosome 10, and deletion in the INK4a gene with loss of
p14 and p16 [14-15]. Progression from low-grade to high-grade astrocytomas involves inac‐
tivating mutations of tumor-suppressor gene TP53 and elevated expression of PDGF ligands
and receptors, accumulation of genetic alteration of retinoblastoma-associated cell cycle reg‐
ulatory pathways, including deletion or mutations of cyclin-dependent kinase inhibitor
p16INK4A/(CDKN2A) or the retinoblastoma susceptibility locus 1 (pRB1), as well as ampli‐
fication or overexpression of cyclin-dependent kinase 4 (CDK4) and human double minute 2
(HDM2). Evolution to secondary GBM is associated with deletion of chromosome 10, which
includes tumor-suppressor phosphatase and tensin homologue (PTEN). PTEN phosphatase
were identified as the tumor suppressors lost on chromosomes 19 and 10, respectively. p16
can slow down cell cycle progression, whereas PTEN is a negative regulator of the phos‐
phoinositide 3-kinase (PI3K) pathway, [16] a major signaling pathway that stimulates cellu‐
lar proliferation in response to growth factor stimulation. Interestingly, only 1 copy of the
gene is mutated in the tumors, suggesting that the mutations do not result in a simple loss of
function. The mutation is very specific and leads to a single amino acid change (arginine 132
usually becomes histidine) in the IDH1 active site, whereby the enzyme loses its ability to
catalyze conversion of isocitrate to α-ketoglutarate. It was proposed that this might have an
indirect oncogenic effect through the activation of the hypoxia-inducible factor pathway,
[17] a critical step in the metabolic adaptation of tumors to anaerobic growth and for the for‐
mation of new blood vessels through the angiogenic process.
Recently, attention has been focused on the role of an enzyme, isocitrate dehydrogenase 1
(IDH1), present in cytoplasm and peroxisomes, catalyzing the oxidative decarboxylation of
isocitrate to alpha-ketoglutarate, reducing NADP+ to NADPH. Studies performed with seri‐
ated biopsies from gliomas, revealed that mutation of IDH1 is always found before TP53
mutation or, in case of oligodendrogliomas, before their typical deletions of chromosomes
1p and 19q. Moreover, mutation of IDH1 is quite specific, since it is extremely rare in I grade
gliomas, non glioma brain tumors and in other cancers. Yan et al. studied genetic alterations
of both IDH1 and of its related gene, IDH2. Genomic analysis, showed mutation of amino
acid 132 of IDH1 in over 70% of patients with both low or high grade gliomas, and many of
the cases negative for IDH1 mutations, had mutation involving amino acid 172 of IDH2 [18].
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Studies suggest that mutant IDH1 loses its normal enzymatic activity in tumors while gain‐
ing a new pro-oncogenic activity, leading to the production of an onco-metabolite [18-20].
Other studies characterizing the genomic make-up of human glioblastoma have provided
further insight into the genetic changes, core pathways and molecular subtypes underlying
this disease [20-22]. Based on their gene expression profiles, The Cancer Genome Atlas Net‐
work (TCGA) further classified GBMs into four subtypes termed: proneural, neural, classi‐
cal, and mesenchymal [9]. While the status of gene expression and mutation in EGFR, NF1,
PDGFA, and IDH1 were defining components of these subtypes, it was also found that re‐
sponse to therapies was different for each subtype, suggesting that personalized treatment
based on genomic alterations could lead to a more favorable outcome for this disease [23].
3. Molecular biology of glioma invasion
The cellular and molecular events that initiate and promote malignant glioma development
are not completely understood. Vasculogenesis and angiogenesis potentially play distinct
roles in the etiology of primary and recurrent malignant gliomas, suggesting that patient
therapy should perhaps be tailored specifically against the predominant vasculature path‐
way at a given specific stage of gliomagenesis [24]. Cerebral gliomas show a unique pattern
of invasion and, with rare exceptions, do not metastasize outside of the brain. Invading glio‐
ma cells normally migrate to distinct anatomical structures. These structures include the
basement membrane (BM) of blood vessels, the subependymal space, the glial limitans ex‐
terna, and parallel and intersecting nerve fiber tracts in the white matter. Invasion of tumor
cells into normal tissue is thought to be a multifactorial process, consisting of cell interac‐
tions with ECM and with adjacent cells, as well as accompanying biochemical processes
supportive of active cell movement. Several cell types aim active movement during various
stages of embryonal development, during wound healing, and in the course of immune re‐
sponses. This innate activity is regulated in a very rigid manner, suggesting that the reap‐
pearance of a motile phenotype in cancer cells results from the loss or cessation of normal
inhibitory controls [25]. Critical factors in tumor cell invasion, include the detachment of in‐
vading cells from the primary tumor mass, the synthesis and deposition of ECM compo‐
nents by tumor cells and mesenchymal cells, the release of ECM-degrading activities for
remodeling interstitial space, and the expression of adhesion molecules on glioma cell surfa‐
ces that specifically recognize and adhere to ECM components.
The detachment of invading glioma cells from the primary tumor mass involves several
events, including, destabilization and disorganization of the cadherin-mediated junctions
that hold the primary mass together, loss of expression of neural cell adhesion molecule,
which promotes adhesion to the primary tumor mass through homophilic binding, cleavage
of CD44, which anchors the primary mass to the ECM by the metalloproteinase ADAM.
Cadherin superfamily are important adhesion molecules associated with glioma invasion.
Cadherins (E-, P-, and N-cadherin) form adherent junctions and may function as suppres‐
sors of tumor growth and invasion. Desmosomal cadherins interact heterotypically and pro‐
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vide a linkage to the intermediate filament network through association with cytosolic
proteins (desmoplakin, plakoglobin). Cadherins are linked to the actin-cytoskeleton via cate‐
nins (α-, β-catenin, plakoglobin), thereby establishing molecular lines of communication to
other cell-cell junctions and to cell-substratum junctions [26]. During glioma progression de‐
creased cadherin function is correlated with de-differentiation, metastasis and poor progno‐
sis [27]. Due to its participation in processes such as morphological differentiation and
contact inhibition of growth and motility, cadherins may function as suppressors of tumor
growth and invasion [25]. Perego and co-worker, showed that only glioma cells with imma‐
ture adherens junctions are capable of migrating and invading through poly-1-lysine coated
filters. In the process of maturation of adhesions, the Lin-7 protein forms a complex with
cadherin and β-catenin [28].
The second step is a decline in the expression of connexin 43, which leads to a reduction in
gap junction formation. Connexin 43 is the most abundant gap junction protein in CNS and
is expressed primarily in astrocytes [29]. Cell-cell communication is important in growth
control and differentiation, and it is partly achieved using gap junctions and via second
messengers [30]. Decreased gap junction formation may result in fewer inhibitory signals,
facilitating uncontrolled cell division and de-differentiation [31]. Has been demonstrated
that reduced gap junction formation is correlated with increased motility of glioma cells in
vitro [32]. Increased malignancy of glioma specimens correlates with reduced in situ gap
junction formation as well as reduced connexin 43 expression [33]. The third event is cleav‐
age of CD44, which anchors the primary mass to ECM, by the metalloproteinase ADAM.
CD44 is a transmembrane glycoprotein belonging to the immunoglobulin receptor super‐
family, which interacts with hyaluronic acid as its ligand. Monoclonal antibodies directed
against CD44 decrease intracerebral invasion of glioma cells in vivo and through matrigel
matrices in vitro [34]. CD44 can be cleaved by ADAM 10 and 17, and both the extracellular
and intracellular cleaved components of CD44 promote cell migration [35].
3.1. Integrins
Integrins are heterodimeric transmembrane cell surface receptors that play a key role in the
crosstalk between the cell and its surrounding stroma. Integrins regulate cell adhesion, mi‐
gration, differentiation, proliferation, and survival during physiological and pathological
conditions, including inflammation and cancer. Upon ligation to extracellular ligands (ma‐
trix proteins such as collagens, laminins, vitronectins and fibronectins), integrins activate
downstream signaling pathways in concert with growth factor receptors, including PDGFR,
EGFR and VEGFR. Preclinical data indicate that integrins play a key role in cancer initiation
and progression.
Integrins contain two distinct chains, calls subunit α (alpha) and β (beta). Have been identi‐
fied about 18 α and 8 β subunits. The integrin subunits penetrate the plasma membrane and
typically have very short cytoplasmic domains of about 40-70 amino acids. Outside the plas‐
ma membrane, α and β chains protrude to a length of about 23 nm, the last 5 of which -
thanks to the termination of each chain formed dall'NH2 - a region used to form bonds to
the ECM. The molecular mass of the subunits of the integrin may range from 90 kD to 160
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kD. The β subunits have 4 cysteine-rich repeat sequences. Both the α subunit β both bind
many divalent cations. There are many ways to classify the integrins. For example, a sub‐
class of the chains α has a structural domain in more inserted at the network termination
NH2, the so-called alpha-domain A. The integrins that possess this characteristic usually
form collagen (α1β1 integrins, and α2β1), or act as adhesion molecules between cell and cell
(β2 integrin family). This domain α-1 is the active site for links to various integrins. Those
who do not carry this domain, however, have a domain A in their active site, but this is in
the β chain. In both cases, the domains A are connected to three active sites consisting of
divalent cations. One of these is permanently occupied by physiological concentrations of
divalent cations, and binds to a calcium ion or magnesium. The other two sites are occupied
by cations when establishing ties - at least for the bonds involving an amino acid, aspartic
acid, typically - in their interaction sites. An amino acid characterized in the active site of the
integrin many proteins ECM, as part of the amino acid sequence Arginine-Glycine-Aspartic
acid. The two main functions of integrins are cell adhesion to ECM and signal transduction
from the ECM to the cell. They interact with two large groups of ligands: a variety of ECM
proteins, such as fibronectin, vitronectin, fibrinogen, and cell surface molecules, that are
members of the immunoglobulin supergene family, such as intracellular adhesion molecules
(ICAM-1, ICAM-2) and vascular cell adhesion molecule (VCAM-1). In particular, the integ‐
rin ανβ3, which binds to fibronectin, vitronectin, and tenascin-C in ECM, is thought to play
a central role in glioma invasion [36]. Increased expression of integrin ανβ3 leads to in‐
creased motility in human glioma cells with a concomitant decrease in apoptosis sensitivity.
Integrins combine the ECM out of the cell to the cytoskeleton (in particular microfilaments)
within the cell. What site can bind the ECM is usually decided by the integrin α and β subu‐
nit which is composed of the same integrin. Bonds between the integrin are fibronectin, vi‐
tronectin, collagen, and laminin. The connection between the cell and the ECM makes the
cell able to withstand the forces tie rods without being thrown out of the ECM. The connec‐
tions between the integrin and the links in the ECM and microfilaments inside the cell are
indirect: they are connected by proteins "armor" as talin, paxillin, and alpha-actinin. These
act by regulating the kinase such as FAK (focal adhesion kinase - focal adhesion kinase) and
the family of Src kinases to phosphorylated substrates such as the p130CAS or recruiting
signal adapters such as Crk. The connection of the cell to the extracellular matrix is a basic
requirement to form a multicellular organism. Integrins link the cytoskeleton to the extracel‐
lular matrix, and are recognized to be key regulators of tissue structure. They provide adhe‐
sive, migratory, and survival cues to tumor cells and to cells of the tumor
microenvironment, including angiogenic endothelial cells. The integrins ανβ3 and ανβ5,
among others, are highly expressed not only on the tumor vasculature and angiogenic endo‐
thelial cells, but also on tumor cells, including gliomas. Consequently, integrins have been
considered as a promising therapeutic target in cancer. Monoclonal antibodies and peptide-
based integrin inhibitors are being investigated for their potential therapeutic activity in var‐
ious tumor types. This strategy is in advanced stage clinical development in glioblastoma, a
highly vascular primary brain tumor [37].
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The malignancy of glioma is dependent on diffusive properties of tumor cells that may in‐
vade widely as single cells anywhere in the brain. Integrins are the family of adhesive recep‐
tors that promote invasiveness of glioma. These heterodimeric transcellular membrane
receptors are composed of two subunits, α and β, and are the major receptors for the ECM
proteins. Immunohistopathological studies revealed an upregulation of α2β1, α3β1, α5β1,
α6β1, and αvβ3 integrins on GBM when compared with normal brain [38].
Glioblastoma commonly displays enhanced expression of several integrins along with their
ECM ligands: αvβ3 and αvβ5 (tenascin and vitronectin receptors), α5β1 (fibronectin recep‐
tor), α2β1 (collagens receptor), and α3β1, α6β4, and α6β1 (laminins receptors). Numerous
studies have focused on the αv integrin family. The integrins αvβ3 and αvβ5 are markers of
glioblastoma malignancy and influence a variety of processes in glioblastoma progression in
vivo, including proliferation, apoptosis, and angiogenesis. Furthermore, cilengitide, an αvβ3
and αvβ5 integrins antagonist, extends mouse survival by delaying the tumor growth and is
nowadays in clinical trial for recurrent malignant glioma. Two other integrins, α5β1 and
α3β1, have been shown to be implicated in glioma cell adhesion and migration in vitro. The
α6 integrin subunit associates with β1 or β4 subunits to form functional heterodimers that
selectively bind laminins. The α6β4 integrin is essential for the organization and mainte‐
nance of epithelial hemidesmosomes that link the intermediate filaments with the extracellu‐
lar matrix. The major ligand of α6β4 is the laminin-332, while α6β1 is a well-characterized
laminin-111 receptor. Overexpression of α6β1 integrin has been associated with the progres‐
sion of many epithelial tumors. Several studies concerning gliomas and the α6β1 ligand
laminin-111 have been reported in the literature. Using immunohistochemistry studies,
Gingras et al. showed that α6 integrin was strongly expressed in glioblastoma tissue, where‐
as it was weakly expressed in normal brain [39]. Previtali et al. confirmed that the expres‐
sion of α6 was increased in glioblastoma and in other central nervous system tumors, such
as meningioma, astrocytoma, and neuroblastoma, when compared with the autologous nor‐
mal tissue counterpart [40]. In glioblastoma biopsies, laminin-111 is highly expressed on tu‐
mor blood vessels, but also within the brain tumor as punctuate deposits and at the tumor
invasion front. In vitro, glioma cells can both secrete laminin-111 and induce its expression
in normal brain tissue. Moreover, laminin-111 is one of the most permissive substrates for
adhesion and migration of glioma cells in vitro. Additionally, over laminin-111, migrating
glioma cells are protected from apoptosis [41].
In malignant glioma, and in particular in GBM, overexpression of αvβ3 integrin is well
documented. The integrin αvβ3, which binds to fibronectin, vitronectin, and tenascin-C in
ECM, is thought to play a central role in glioma invasion [36]. Increased expression of integ‐
rin αvβ3 leads to increased motility in human glioma cells with a concomitant decrease in
apoptosis sensitivity. Importantly, αvβ3 integrin is expressed both on angiogenic endothe‐
lial cells and on tumor cells. Conversely, inhibition of integrin αvβ3 decreases glioma cell
motility [42]. Several factors expressed in glioma cells have been found to regulate integrin
expression. Particularly, uPA secreted by glioma cells has been shown to upregulate integrin
αvβ3 expression by autocrine mechanism [43]. Furthermore, decreasing the in vivo expres‐
sion of the β1 subunit by an antisense strategy in the intracranial C6 glioma model leads to
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an inhibition of glioma associated angiogenesis at the invasive edge of the tumors [44].
Down-regulated β1 integrin protein levels in vivo probably affect interactions of glioma
cells with ECM components, leading to reduced migration along vascular basement mem‐
branes. The integrin α6β1 plays an important role for the regulation of glioma-initiating cells
in the perivascular niche. This integrin mediates the interaction of glioma-initiating cells to
laminin, an extracellular matrix protein expressed in basement membranes, including those
supporting endothelial cells. This interaction provides an anchorage for glioma-initiating
cells within the perivascular niche and supports their tumorigenic potential [37].
Brown  et  al.  evaluate  the  role  of  α9β1  integrin  interaction  with  nerve  growth  factor
(NGF)  in  glioma  progression,  they  selected  the  two  most  malignant  glioblastoma  cell
lines: LN229, which expresses α9β1, and LN18,in which does not. Presence of the α9 in‐
tegrin subunit on LN229 and absence on LN18 cell  lines were verified using several as‐
says  such  as  monoclonal  antibody  adhesion  microarray,  Western  blot  analysis  of  cell
lysates, flow cytometry, and immunocytostaining [38]. Very high expression of the α9 in‐
tegrin  subunit  was  observed  only  on  the  LN229  cell  line.  Western  blot  analysis,  using
polyclonal anti-α9 antibody, showed the absence of this integrin subunit on normal astro‐
cytes.  The expression of α9β1 integrin on LN229 and lack of it  on LN18 was confirmed
by  flow  cytometry  and  immunocytostaining  analysis.  The  investigation  of  cellular  re‐
sponses  following binding of  NGF to  α9β1 integrin  on LN229 and LN18 cells  required
evaluation of the level of two other NGF receptors, TrkA and p75NTR. Western blot analy‐
sis  of  cell  lysates  and  immunocytostaining  revealed  negligible  expression  of  TrkA  on
both types of cells, and a stable expression of p75NTR  in comparison with PC12 neuronal
cells used as a positive control. Interestingly, the level of p75NTR appeared to be lower on
LN18 cells, which are α9β1 integrin deficient, than on LN229 cells, which are α9β1 integ‐
rin positive. This correlation was previously observed in the mRNA level of SW480 cells
transfected with α9 integrin subunit. Cells transfected with the α9 subunit showed a po‐
tent  increase of  p75NTR,  whereas mock-transfected cells  had a significantly lower expres‐
sion of this NGF receptor. The opposite situation occurred for TrkA, suggesting that this
specific high affinity NGF receptor has a functional complementary association with α9β1
integrin.  Several  factors  expressed in  glioma cells  have  been  found to  regulate  integrin
expression.  Glioma expression of  focal  adhesion kinase,  a  nonreceptor cytoplasmic tyro‐
sine kinase, has been shown to increase phosphorylation of the enhancer of filamentation
1,  which  in  turn  stimulates  PDGF-mediated  stimulation  of  glioma  integrin  adhesion  to
ECM [45].
3.2. Proteases
Extracellular proteolytic enzymes are critical for the invasive properties of malignant neo‐
plasms [46]. Barrier to invasion do not appear as restrictive within CNS parenchyma and
matrix substrates most responsible for impeding tumor migration have not been identified
[47]. Nonetheless, there is a strong evidence that the expression of specific extracellular ma‐
trix proteases promotes invasive behavior by gliomas. These include the matrix metallopro‐
teinases (MMPs), the urokinase-dependent plasminogen activating cascade, and cathepsin
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B. Wild-Bode et al. [48] found that MMP-2 and MMP-3 levels and MMP-2/MMP-9 activity
correlated with glioma cell migration and invasion. NF-jB, uPA, low-density lipoprotein re‐
ceptor-related protein 1, and insulin-like growth factor binding protein-2 are known to upre‐
gulate MMP expression. Induced expression of tissue inhibitor of metalloproteinases-3
(TIMP-3), a putative inhibitor of MMP activity, has been shown to suppress infiltration and
also to induce apoptosis in cancer cell lines. MMPs play an important role in human brain
tumor invasion, probably due to an imbalance between the production of MMPs and tissue
inhibitor of metalloproteinases-1 (TIMP-1) by the tumor cells. MMP-1 is the crucial enzyme
able to initiate breakdown of the interstitial collagen types; in this way, it activates the other
MMPs, which allows the glioma cells to infiltrate normal brain tissue.
Matrix metalloproteinases comprise a large family of zinc-dependent endoproteinases, col‐
lectively capable of degrading all ECM components. A total of 23 families of MMPs are
known and these are numbered in the sequence of their discovery [49]. Originally, MMPs
were classified according to their respective substrate specificity, now they are divided into
eight structural subgroups, five of which are secreted and three of which are transmem‐
brane MMPs. A signal peptide leads them to the secretory pathway. Then, these enzymes
can be secreted from the cell or anchored to the plasma membrane, thereby confining their
catalytic activity to the extracellular space or to the cell surface, respectively. Their function
is to degrade different protein components of the ECM and of basement membranes, there‐
fore they are essential for the interaction of individual cells with their surrounding and for
the development and function of multicellular organisms [50]. Between the various sub‐
strates of MMPs we include collagens, non collagens glicoproteins, proteoglycans and other
ECM components like tenascin, fibronectin and laminin, which often show tumor specific
expression are also substrates [51]. The proteolytic activities of MMPs influence essential cel‐
lular processes like cell proliferation, migration and adhesion, as well as many fundamental
physiological events involving tissue remodeling, such as angiogenesis, bone development,
wound healing, and uterine and mammary involution [52]. However, the increasing expres‐
sion of this enzymes is associated with many pathological conditions [53-54] such as rheu‐
matoid arthritis, cardiovascular diseases or cancer progression [55]. MMP expression and
activity can be regulated at different levels including gene transcription, proenzyme activa‐
tion and endogenous inhibition, which act in a coordinated manner to confine the diverse
MMP proteolytic activities to those conditions and locations where they are necessary. Un‐
fortunately, these restrictive regulatory mechanisms are frequently lost in multiple patho‐
logical conditions [56]. MMPs expression is induced by different factors like EGF, TGF-β,
PDGF, and various inflammation’s mediated, included TNFα and IL-1β.
MMPs or matrixins are synthesized as zymogens, inactive pro-enzymes (pro-MMPs), with
the zinc ion, essential for MMP activity, hidden by a cysteine-sulphydryl residue situated
near the C-terminal end of the peptide. The pro-enzyme’s activations starts breaking the in‐
teraction cysteine-zinc exposing, in this way the catalytic site. The fully active enzyme is
generated by proteolytic cleavage of the pro-peptide domain of the partially active inter‐
mediate enzyme [50]. Once active, MMPs are regulated by interactions with endogenous in‐
hibitors including α2-macroglobulin, thrombospondin-2, tissue inhibitors of metallopro-
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teinases (TIMPs) and RECK (reversion-inducing cysteine-rich protein with kazal motifs)
[49]. Numerous studies have investigated the expression of selected MMPs in human GBM
cell lines. As it has already been reported that there are differences in the expression pat‐
terns of MMPs in different cell-lines [57]. A number of different techniques have been used
to detect protease expression patterns. This may have led to dissimilar conclusions, due to
disparate sensitivities and due to comparing mRNA expression with protein expression or
protein activity. Variations in MMP expression may be due to in vitro selection processes or
karyotype evolution, where the transcription of either the enzyme and/or its inhibitor may
be affected which ultimately leads to an imbalance in the MMP-regulatory network [57].
MMP-9’s production is dependent on a regulation by extracellular signal-regulated kinase
(ERK), PKCα/NF-κB and jun amino-terminal kinase (JNK) signaling cascades. Glioblastomas
are highly hypoxic and hypoxia upregulates MMP-2 mRNA expression in U87, U251, U373
and LN18 glioblastoma cell-lines by activation of the HIF-1α transcription factor, thereby en‐
hancing their invasive potential. Migration and invasion of U87 and T98G GBM cells is also
facilitated by NO, which can be found in high concentrations in glioblastoma tissue. NO
stimulates MMP-1 expression and activity. EGF raises MMP14 expression in U251 cells, but
does not influence MMP-15, -16 or MMP-24. MMP-2 expression and secretion is induced by
IL-6 in U87 cells. However, IL-6 action seems to be cell-line specific, since U343 cells were
not affected [57].
The inflammatory cytokine TNF-α and the immune-suppressive cytokine TGF-β have been
implicated in migration and invasion of glioma cells in vitro. In U251 and in U373 cells,
TNF-α stimulated the expression of MMP-9 and MMP-19. MMP-1 mRNA expression was
significantly increased in U373 cells by TNF-α, whereas its expression in U251 cells re‐
mained unaffected. This may be due to the high basal level of MMP-1 expression displayed
by U251 cells, where a further increase is not possible, or else it could also be a cell- line spe‐
cific effect. Such an effect has been observed for MMP-1, -2, -3 and MMP-7 regulation by
TNF-α and TGF-β1, which only caused a marked induction of expression in some GBM cell-
lines. TNF-α enhances the invasiveness of T98G cells through an induction of MMP-3, but
has no effect on MMP-1, -2 or MMP-9. However, in U251 cells TNF-α inhibits MMP-2 and
decreases invasiveness into the extracellular matrix. In A172 cells, TNF-α induces gene ex‐
pression and protein secretion of MMP-9. TGF-β1 alone had no effect on MMP-9 production.
However, when it was added together with TNF-α a significant dose-dependent inhibition
of MMP-9 secretion was observed. TGF-β1 displayed inconsistent effects on adhesion and
invasiveness, depending on the cell-line examined. The invasive potential of U138 cells was
markedly reduced, whereas U373 cell invasion remained unchanged. TGF-β1 caused a sig‐
nificant induction of MMP-11 and MMP-24 expression in U373 cells, whereas there was no
impact on MMP expression in U251 cells. In U87 and LN229 cells, TGF-β upregulates
MMP-2. Thus, the transcriptional modulation of MMP genes in response to TNF-α or TGF-β
is not consistent, but extremely cell-line specific [57]. Elevated levels of several MMPs were
also found in malignant glioma tissue samples. MMP-1 expression was increased in surgical
specimens of GBM compared to low grade astrocytomas and normal brain. This increased
expression is probably due to a single nucleotide polymorphism in the MMP-1 promoter at
position-1607, creating a functional binding site for members of the ETS family of transcrip‐
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tion factors. MMP-1 was expressed throughout the tumor section, particularly in the highly
cellular areas of the GBM [57]. Many studies have demonstrated an intimate association be‐
tween MMP-9 and tumor invasiveness. Different analyses for MMP-9 were negative in NB
tissue, showed weak signals in LGA and strong expression in GBM [57]. MMP-9 is strongly
expressed in blood vessels at proliferating margins, as well as tumor cells, this suggests a
role in the regulation of tumor neoangiogenesis [58]. Other proteases that could be related
with the development of highly invasive glial tumor are MMP-11, MMP-12, MMO-14,
MMP-15, MMP-19, MMP-24, MMP-25.
A second proteolytic system that interfaces with MMPs is the urokinase pathway of plasmi‐
nogen activation. This system includes urokinase (also known as urokinase-type plasmino‐
gen activator, uPA), the urokinase receptor (uPAR), and plasminogen. Urokinase is secreted
as a single chain, inactive proenzyme that is activated by cleavage upon binding to its cell
surface receptor uPAR. Activated uPA then converts plasminogen into plasmin, a serine
protease that promotes cellular migration by the degradation of extracellular matrix pro‐
teins, activation of other matrix proteases and activation of cell surface receptors that trans‐
duce intracellular signaling for migration. Plasmin activates protease activated receptor 1
(PAR1), which is normally expressed in human astrocytes, is activated in many malignan‐
cies including GBMs, and is associated with increased invasive properties [59]. Thus, uPA
and plasminogen activation can occur in the immediate vicinity of the cell membrane or, fol‐
lowing cleavage of the uPAR GPI anchor, at greater distance in the extracellular matrix. An
important biologic regulator of this cascade is plasminogen activator–inhibitor 1 (PAI1),
which promotes the internalization of uPA bound uPAR [60]. uPAR has roles in cellular mi‐
gration distinct from its ability to activate plasminogen though its interactions with integ‐
rins, signaling through G-protein coupled receptors, and caveolin binding [61]. There is a
convincing correlative relationship between uPAR and uPA expression and malignant pro‐
gression in a variety of tumor types [62]. Both neoplastic cells and stromal cells contribute to
the overall activity of these pathways. In co-cultures of malignant gliomas and reactive as‐
trocytes, most uPA and uPAR activity was derived from reactive astrocytes, whereas plas‐
minogen was expressed in largest amounts by glioma cells [63]. Levels of uPA mRNA and
its enzymatic activity are higher in human anaplastic astrocytomas and GBMs than in low
grade astrocytomas and normal human brain and uPA mRNA levels have an inverse corre‐
lation with survival periods [64]. uPAR levels are significantly higher in GBMs and anaplas‐
tic astrocytomas that normal brain and low grade gliomas, with uPAR mRNA localizing to
both glioma cells and endothelial cells [65]. The finding of uPAR expression at the leading
edge of neoplastic infiltration and within remodeling hyperplastic blood vessels suggested
that it may be playing a role in invasion and tissue remodeling. mRNA levels of both uPA
and uPAR genes are increased in high grade gliomas possibly suggesting increased gene
transcription [66]. In the CNS, reactive astrocytes in the vicinity of invading gliomas appear
to contribute for a substantial proportion of extracellular MMP activity, both by their secre‐
tion of pro-MMP2 and the components of the plasminogen activating system, uPA and uP‐
AR [63]. Reactive astrocytes have also been shown to promote the invasive capabilities of
glioma cells in vitro, presumably resulting from enhanced extracellular MMP-2 activity.
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The cathepsins are a family of lysosomal cysteine proteases. These proteases are synthesized
as inactive pro-enzymes that are activated by autocatalytic activity initiated by low pH or by
other proteases including cathepsin D, uPA, and pepsin. Natural regulators of cathepsins
are the cystatins, which are critical, in their inhibitory properties. Cathepsins are secreted in‐
to the extracellular space where they degrade extracellular matrix components required for
invasive properties in neoplastic disease. Best studied for their roles in glioma tumorigenesis
and invasion are cathepsins B, D, H, L, and S. Each of these cathepsin subtypes have higher
protein levels in high grade astrocytomas than low grade tumors or normal brain and enzy‐
matic activities, in general, correlate with protein expression [67-68]. The role of cathepsins
in tumor invasion has been supported by the finding that tumor cells at the invading edge
of gliomas express high levels of cathepsins, especially cathepsin B [69]. In addition, protein
and enzymatic levels of cathepsins B, D, L, H, and S were found to correlate with the ability
of glioblastoma cells to migrate in vitro. Once in the extracellular compartment, cathepsin B
physically interacts with a protein complex at the outer cell membrane containing annexin
II, p11, tPA and plasminogen [70]. Its close proximity to both the plasminogen activating
cascade and MMPs is critical for regulation of their combined proteolytic functions. Upon
activation, cathepsin B has its own proteolytic activity on extracellular matrix components,
but also activates the cascade to convert plasminogen to plasmin and is able to activate se‐
lected MMPs [71].
3.3. Extracellular matrix
The ECM affects numerous functions and processes within the brain. During brain develop‐
ment, the ECM modulates the migration of glial and neuronal precursor cells, guides axonal
growth cones, synapse formation and cell proliferation. The roles played by the ECM in neo‐
plastic transformation are complex and only now beginning to be uncovered. ECM is a com‐
plex network of different collagens, proteoglycans, hyaluronic acid, laminin, fibronectin,
and many other glycoproteins, including proteolytic enzymes involved in degradation and
remodelling of the ECM [72]. Extracellular matrix exists in two forms: interstitial matrix that
fills in the intercellular space and the more specialized BM, which is a thin sheet of extracel‐
lular matrix underlying the epithelium. ECM provides the microenvironment for the cells
and serves as a tissue scaffold, guiding cell migration during embryonic development and
wound repair. Integrins are a class of adhesion molecules that have a major role in the adhe‐
sion and subsequent invasion of tumor cells. ECM proteins such as fibronectin, laminins or
collagens form distinct protein networks that show tissue-specific variation in composition
and architecture. Cell responses to contact with these networks depend on the cell’s reper‐
toire of ECM receptors. Connections from the matrix through these receptors determine the
organization of cytoskeletal structures and the localization and activation of signaling mole‐
cules leading to unique tissue specific cell functions. Changes in these ECM components are
felt to modulate brain tumor growth, proliferation and invasion, although specific interac‐
tions and exact mechanisms are unknown. Cell adhesion is the binding of the cells to each
other and to the ECM through cell adhesion molecules such as integrins, selectins, cadher‐
ins, the Ig (immunoglobulin) superfamily and lymphocyte homing receptors. Cell adhesion
mediates cell attachment, migration, and signalling to and from the extracellular matrix. Ad‐
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hesion complexes include focal adhesions, adherens junctions, tight junctions, desmosomes,
hemi-desmosomes, and gap junctions. The best characterized adhesion molecules are the in‐
tegrins and the best characterized adhesion complexes are focal adhesions. The extracellular
ligands that anchor these adhesions include laminin, fibronectin, vitronectin, and various
collagens. Focal adhesions can be considered both as sensors of force and as sites that origi‐
nate cytoskeletal forces through anchored actin-microfilament bundles. Focal adhesions
have many SH2-containing components (Src kinases, PI3K, SHP-2), as well as many tyro‐
sine-phosphorylated molecules (focal adhesion kinase paxillin, tensin, caveolin).
Syndecans are a family of transmembrane heparin sulphate proteoglycans with four mem‐
bers, syndecans 1 to 4. Syndecans function mainly as co-receptors by binding to their ECM
ligands in conjunction with other receptors, notably integrins. Through their heparin sul‐
phate side chains, syndecans may further engage directly in ligand binding. Dystroglycans
are heterodimeric complexes consisting of non-covalently associated α and β subunits with
extracellular ligand-binding and transmembrane functions, respectively. Dystroglycans are
a part of the larger dystrophin-associated protein (DAP) complex that connects basement
membranes to the cytoskeleton, particularly via α2 laminins and perlecan. Ig superfamily
members consist of immunoglobulin-like and fibronectin type III domains involved in ho‐
mophilic and heterophilic cell–cell adhesion. The superfamily includes a variety of cell ad‐
hesion molecules (CAMs) with distinct ligand-binding specificities, including ICAM
(intercellular), NCAM (neural), Ep-CAM (epithelial), L1-CAM, VCAM (vascular), ALCAM
(activated leukocyte), and JAM (junctional adhesion molecule), among others. Cadherins are
transmembrane proteins consisting of several tandemly repeated cadherin domains that me‐
diate calcium-dependent homophilic cell-cell contacts. The cadherin superfamily comprises
a total of more than 100 different members, with E- (epithelial) and N-cadherin (neural)
most widely expressed in epithelial and neural tissues, respectively [73].
By convention, ECM components are biochemically classified fibrillar proteins (collagens),
glycoproteins (laminins, fibronectin, tenascins), and several classes of proteo- glycans (hep‐
aran sulfate-, chondroitin sulfate-, dermatan sulfate-, and keratan sulfate proteoglycans).
The latter mainly consist of large glycosaminoglycan (GAG) chains, covalently linked to ex‐
tra- cellular or membrane bound core proteins. In contrast to other tissues, the ECM in the
CNS lacks fibrillar proteins under physiological conditions. Instead the neural ECM is rich
in glycoproteins and proteoglycans. It has been estimated that the neural ECM makes up
about 20% of the CNS parenchyma [74]. The brain ECM is mainly deposited by astrocytes
and oligodendrocytes and comprises an estimated 20% of the brain volume in adults. The
main ECM components are hyaluronic acid (HA), tenascin R, and lecticans, which intercon‐
nect with each other noncovalently and form molecular networks filling the intercellular
space. HA is a non-sulphated, linear, high-molecular weight glycosaminoglycan which, due
to its water-binding capacity, controls the high water content of the brain interstitium. Be‐
sides tenascins and lecticans, HA binds to cell surface receptors including CD44 and
ICAM-1, which together contribute to both ECM organization and cell-matrix interaction. It
represents the major component of neuropil ECM and is widely distributed in the adult and
embryonic brain. Malignant gliomas contain higher amounts of HA than low-grade gliomas
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in situ and in vitro, while the perivascular location in glioma biopsy suggests additional
production by vascular stromal cells [75].
The tenascins (TN) are a family of large multimeric ECM proteins consisting of repeated
structural modules including heptad repeats, epidermal growth factor (EGF)-like repeats, fi‐
bronectin type III repeats, and a globular domain shared with the fibrinogens. The TN are
presumably involved in the morphogenesis of many organs and tissues [76-77]. The original
tenascin discovered was TN-C, partially because of its overexpression in tumours and, infer‐
ring from cell biological studies, it has been proposed as an adhesion-modulating protein
[77]. TN-C (also called neuronectin, brachinectin, myotendinous antigen, hexabrachion, glio‐
ma-mesenchymal extracellular matrix antigen, cytotactin, J1 protein, GP250 protein) has a
characteristic hexabrachion structure, with as many as six arms linked to a central knob
formed by disulfide bonding of cysteines in the NH2-terminal ends of polypeptides. TN-C
initially appears during embryonic neural crest cell development, and it is present during
brain and spinal cord organogenesis, being correlated with developmental phenomena such
as cell proliferation, migration, and ECM remodelling. In addition, TN-C is transiently
present in the dense mesenchyma surrounding several developing organs and tissues, in‐
cluding the nervous system [76-77]. Enhanced TN-C expression was detected among tu‐
mour cells, around individual cells as a fibrillary network, and around vascular channels
[78]. A direct relation between the presence of TN-C and the degree of malignancy of glio‐
mas has been reported, being TN-C reported to be expressed 5-fold higher in GBM as com‐
pared with AA and 10-fold higher as compared with juvenile pylocitic astrocytoma [79-80].
Endothelial cells in vitro attach to TN-C substrata, where they elongate, extend, and have
interconnecting process. These features are lacking when endothelial cells growth on other
matrix proteins, such as fibronectin, collagen, or laminin. The attachment of endothelial cells
to TN-C is mediated by annexin and integrins, including ανβ3 integrin, which is required
for angiogenesis [79-81]. Tenascin R, another brain-specific member of the tenascin family, is
a homotrimer with both lectican and integrin binding sites forming an adhesion bridge be‐
tween the ECM and cells. Lecticans comprise a family of chondroitin sulphate proteoglycans
with four members (brevican, versican, neurocan, and aggrecan), whereby brevican and
neurocan are brain-specific. Lecticans contain HA and tenascin R binding sites and thus act
as link molecules in protein–proteoglycan–glycosaminoglycan networks. Compared with
peripheral interstitial tissues, a distinctive feature of the brain ECM is the absence of fibrillar
collagen networks, which results in a low stiffness of the brain parenchyma. In a restricted
expression pattern, fibrillar collagens I and III are, however, deposited by leptomeningeal
cells, pericytes, and smooth muscle cells in blood vessels and the brain meninges, including
the pia mater.
Fibronectin (FN) is a member of a family of glycoproteins that show many biological func‐
tions, including normal cell adhesion, growth, and migration. FN is involved in many cellu‐
lar processes, including tissue repair, embryogenesis, blood clotting, and cell migration/
adhesion. Both decreased expression and elevated degradation of FN have been shown to be
responsible for some of the morphological changes observed in tumors and tumor-derived
cell lines. As a peripheral protein, FN mainly acts as a bridge to link the cell surface and
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ECM. Therefore, the absence or reduction of FN in tumor cells may reduce the adhesion be‐
tween tumor cells and matrix components, and decrease the matrix's control of cell differen‐
tiation, proliferation, and migration. As a major protein in blood and as component of the
wound provisional matrix, plasma FN contributes to tissue repair and neuronal survival fol‐
lowing cerebral ischemia [82]. Fibronectin structure is rod-like, composed of three different
types of homologous, repeating modules, types I, II, and III. These modules comprise func‐
tional domains that mediate interactions with other ECM components, with cell surface re‐
ceptors and with FN itself. Twelve type I modules make up the amino-terminal and
carboxy-terminal region of the molecule, and are involved mainly in fibrin and collagen
binding. Only two type II modules are found in FN. They are instrumental in binding colla‐
gen. The most abundant module in FN is type III, which contains the RGD-FN receptor rec‐
ognition sequence along with binding sites for other integrins and heparin. Depending on
the tissue type and/or cellular conditions, the FN molecule is made up of 15-17 type III mod‐
ules. In addition, there is a module that does not fall into any of these categories, called II‐
ICS. This module, along with EDB and EDA is regulated through alternative splicing of FN
pre-mRNA. FN is an important component in the ECM of gliomas, largely in the vessel wall
[83]. Expression of FN has been characterized in human GBM and in a number of astrocyto‐
ma and glioblastoma cell lines. In a study of pediatric GBM, a marked positive staining of
FN in walls of small and medium size vessels was demonstrated. FN expression was seen in
perivascular sheets, where it looked like a fine irregular network [83]. Knott et al. found that
when normal brain tissues were invaded by glioma, ECM components such as LN, FN, and
collagen type IV may are available and that tumor cells may express specific integrins, de‐
pending on the change of the interior environment, to interact with these ECM components,
and enhance tumor cell invasion [84]. In vitro experiments have proven that components of
ECM, LN and FN, can strongly stimulate the migration of glioma cells, which occurs after
glioma cells express the relevant surface receptors [85]. Although there are many in vitro
and in vivo models for FN-promoted invasion and transmigration [85], the uniqueness of
these findings may be attributed to interaction between tumor cells and vascular endothelial
cells (VECs), as changes of tumoral microenvironment molecules can affect tumor status and
progression. Recently it has been demonstrated that FN expression is correlated with glioma
migration and glioma malignancy [86]. More recently, FN has been reported to mantain ex‐
tracellular matrix rigidity to promote structural rigidity, motility, and proliferation of estab‐
lished glioma cell lines in vitro [87]. The inhibition of FN expression in glioma cells, using
short hairpin RNA-mediated silencing of gene expression, delayed cell proliferation in vitro.
This delayed growth is explained, in part, by the observed reduced expression of integrin ß1
FN receptor, which was restored by the inhibition of proteosomal activity [88].
LM are a group of adhesion structural glycoproteins found in all BM as an integral part of
the glia limitans externa [89]. LM the first neurite outgrowth promoting ECM identified is
an adhesion glycoprotein associated with the development and regeneration of neuroecto‐
dermal tissues [89]. LM is distributed beneath vascular endothelial cells, around vascular
smooth muscle cells, in the glia limitans, and beneath choroid plexus epithelial cells and
plays a role in migration, neurite outgrowth, proliferation, and differentiation [90]. LM con‐
stitute the preferred substrate for growth of astrocytes and neurons, and have been found in
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all BM and in hyperplastic blood vessels in gliomas, gliosarcomas, and meningiomas [89].
Reactive astrocytes in situ, glioma cells in situ, as well as glioma cells lines, have been re‐
ported to express LM. Variants of LM may be expressed by astrocytes or neurons under dif‐
ferent situations which adds to the complexity of the function and regulation of these large
molecules in the CNS [91].
Type IV collagen (C-IV), the principal collagenous constituent of most BM, is mainly present
in capillaries and large blood vessels. C-IV is associated with laminin, entactin, and the hep‐
aran sulphate proteoglycans perlecan. C-IV is found in areas of the normal brain, such as,
beneath vascular endothelial cells, around vascular smooth muscle cells, in the glia limitans,
and beneath choroid plexus epithelial cells. GBM cells are able of synthesising C-IV in vitro
[72]. Bjerkvig et al. [92], demonstrated that C-IV was strongly expressed in tumour sphe‐
roids from rat glioma cell lines BT4C. In vitro the presence of C-IV in tumour vessels has
been used to demonstrate vascular abnormalities in gliomas, such as BM duplication and
disruption, as well as increased vascular density [93]. Recent studies have shown that GBM
cells around areas of vascular proliferation, are also able to synthesise C-IV localised to the
subendothelial BM of blood vessels [72].
4. Angiogenesis
Physiological angiogenesis, the formation of new blood vessels from pre-existing ones, is a
strictly regulated fine-tuned process. The local balance between inducers and inhibitors of
angiogenesis is critical in determining the generation or not of new vessels. Whenever this
balance is perturbed pathological, uncontrolled, excessive angiogenesis occurs. Angiogene‐
sis is a process that plays an essential role in cancer development. Coagulation and inflam‐
mation also play an important role in tumorigenesis. Their expression is controlled by over-
or under-expression of certain genes [94]. Although a plethora of molecules can act as
inducers of angiogenesis such as acidic fibroblast growth factor (aFGF), basic fibroblast
growth factor (bFGF), transforming growth factor alpha and beta (TGF-a and -h), tumor ne‐
crosis factor alpha (TNFα) and interleukin-8 (IL-8), the major growth factors specific for vas‐
cular endothelium include members of the vascular endothelium growth factor (VEGF) and
angiopoietin families, and at least one member of the large ephrin family.
Angiogenesis is believed to be the primary method of vessel formation in gliomas. Malig‐
nant gliomas are characterized by extensive microvascular proliferation. Neovascularization
in brain tumors correlates directly with their biological aggressiveness, degree of malignan‐
cy and clinical recurrence and inversely with the post-operative survival of patients affected
by gliomas. Among all solid tumors, GBM has been reported to be the most angiogenic by
displaying the highest degree of vascular proliferation and endothelial cell hyperplasia.
Such intense vascularization might be responsible for the peritumoral edema, one of the
pathological features of GBM [95]. The presence of endothelial glomeruloid-like prolifera‐
tion and of positive immunoreaction at level of BM of tumor vascular channel are predictive
of active tumor invasiveness [83]. Diffuse astrocytomas tend to progress from grade II to
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grade III tumors with a time interval of several years, whereas, progression of grade III to
grade IV is more rapid, typically 2 years. Primary and secondary GBMs are morphologically
indistinguishable and show their histologic hallmarks, i.e., “glomeruloid” microvascular
tufts and necrosis. Glioma vasculature is structurally and functionally abnormal and it cor‐
relates and leads to vasogenic edema, increased interstitial pressure, and heterogeneous de‐
livery of oxygen and drugs [96].
Neoangiogenesis may be quantified post-operatively in brain tumors by the evaluation on
surgical samples of the so-called microvessel density (MVD), which reflects the number of
vessels per mm2 within representative histological sections. Specifically, MVD is assessed in
formalin-fixed and paraffin-embedded tissue sections through standard immunohistochem‐
istry; in detail, the vessels present in the histological sections are preliminarly highlighted
with peroxidase-conjugated antibodies against endothelial markers and then they are count‐
ed at light microscopy. Antibodies against several endothelial markers, such as Factor VIII,
CD31, CD34 and endoglin, may be used for the quantification of MVD, with different sensi‐
tivity and specificity. For instance, following the use of antibodies against pan-endothelial
markers (Factor VIII, CD31, CD34), all the vessels present in the histological section are
stained, with no distinction between pre-existing and newly-formed vessels [97]. As a conse‐
quence, pan-endothelial cannot be considered as optimal markers for the quantification of
neoangiogenesis. In contrast, endoglin (CD105), a 180-kDa transmembrane homodimeric
glycoprotein that belongs to the TGF receptor complex [98], appears as an endothelial mark‐
er which more specifically allows the detection of vessels related to neoangiogenic process
in brain tumors [97, 99-101]. Indeed, this protein is predominantly expressed by the cycling
endothelial cells in the vessels of tumors [102]; even more the antibody against endoglin pre‐
fentially binds the activated endothelial cells of peri- and intra-tumor vessels that are actual‐
ly involved in tumor neoangiogenesis, while a negative/weak immunoreaction for endoglin
is evidenced in the vascular endothelium of normal tissues [97, 102]. Besides, in comparative
studies, antibodies against endoglin have been demonstrated to be more specific in the de‐
tection of newly formed vessels in meningiomas [97], as well as in astrocytic [100] or oligo‐
dendroglial [101] neoplasias in comparison to those binding pan-endothelial markers. In
addition, when MVD was assessed by using endoglin as a marker of angiogenesis, it ap‐
peared to be significantly correlated to the growth fraction and histological grade of menin‐
giomas, and it was shown to have a prognostic impact on the overall survival and
recurrence risk of these neoplasias [97]. Thus, we suggest the use of anti-endoglin antibodies
instead of that of antibodies against pan-endothelial markers for the quantification of angio‐
genesis in brain tumors. Besides, the demonstration of endoglin expression in tumour ves‐
sels may also open therapeutic prespectives. Indeed, it has been recently shown that
monoclonal antibodies against endoglin are able to induce tumour growth regression
through the inhibition of the endothelial cells proliferation and angiogenesis itself [103].
The first phase in forming new blood vessels from existing vessels is the dissolution of as‐
pects of native vessels. Glioma cells first accumulate around the existing cerebral blood ves‐
sels and lift off the astrocytic foot processes, which leads to the disruption of the normal
contact between endothelial cells and the basement membrane [104]. The affected endothe‐
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications56
lial cells express angiopoietins resulting in destabilization of the vessel wall and decreased
pericyte coverage. The angiopoietins are endothelial growth factors and their signal trans‐
duction pathway passes via the Tie2 receptor tyrosine kinase expressed on endothelial cells.
In particular, Ang-1 and -2, have been implicated in glioma angiogenesis [105]. Ang-1 medi‐
ated activation of Tie2 is required for stabilization, remodeling and maturation of blood ves‐
sels, promotes angiogenesis and tumor growth and is associated with an increased number
of highly branched vessels. Ang-1 induces phosphorylation of Tie2 and the p85 subunit of
PI3K and increases PI3K activity in a dose-dependent manner, leading to endothelial cell
survival via Akt signaling. In addition, Ang-1 stimulates endothelial cell migration via a
PI3K-dependent activation of focal adhesion kinase (FAK), which has a key role in regulat‐
ing dynamic changes in actin cytoskeletal organisation during cell migration. The biological
effect of Ang-2 may depend on VEGF level. In the presence of endogenous VEGF, Ang-2
promotes vessel dilatation, remodelling of the basal lamina, proliferation and migration of
endothelial cells, and stimulates sprouting of new blood vessels. In the absence of VEGF ac‐
tivity, Ang-2 becomes anti-angiogenic by promoting endothelial cell death and the regres‐
sion of vessels [105]. Binding of Ang-2 to the Tie2 receptor on endothelial cells antagonizes
this receptor’s phosphorylation, thereby disrupting contacts between endothelial and peri‐
endothelial support cells and disengaging pericytes from the tumor vessels during initiation
of vessel sprouting or regression. Increased expression of Ang-2 on GBM microvasculature
appears early during glioma angiogenesis. Ang-2 and Tie2 expression are absent in the nor‐
mal brain vasculature but are induced in tumor endothelium of coopted tumor vessels prior
to their regression. Treatment of glioma cell derived mouse xenografts with a dominant neg‐
ative form of Tie2 results in a significant decrease in tumor growth [106]. Maintenance of an
optimal number of pericytes is necessary for successful angiogenesis in stabilizing newly
formed vessels from further sprouting and to support adequate blood flow. Ang-2 may act
as an antagonist to Tie2 phosphorylation, leading to destabilization of blood vessels. There‐
fore, Ang-2 represents a checkpoint for Ang-1/Tie2-mediated angiogenesis [107]. In brain tu‐
mor growth it’s possible observe two vascular phases. In the first, the vessels are native
cerebral vessels, which are co-opted by tumor cells, while in the second phase, there is true
neovascularization arising from existing vessels. During the transition period between these
two phases, hypoxia driven HIF-1 expression occurs which results in VEGF secretion and in
the induction of neovascularization. In stage IV, angiogenesis adjacent to the necrotic area is
triggered in response to increased expression of HIF-1α and VEGF. For the newly sprouting
vessel is essential the deposition of proangiogenic matrix. This involves breakdown of the
vascular basement membrane and extracellular matrix through the action of cathepsin B,
matrix metalloproteases and other enzymes as well as the expression of matrix proteins such
as fibronectin, laminin, tenascin-C and vitronectin [108]. Degradation of the vessel basement
membrane and surrounding ECM, which also facilitates the invasion of endothelial cells, is
an integral part of the ongoing angiogenic process. The matrix metalloproteinase family en‐
zymes that degrade components of ECM consist of four groups according to their sub‐
strates: collagenases, gelatinases, stromelysins, and membrane-associated MMPs.
Gelatinases-A (MMP-2) and gelatinases-B (MMP-9) are highly expressed in astrocytomas,
and their expression levels, especially those of MMP-9, correlate with the histological grade
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of tumor. MMP-2 and MMP-9 expression is strongly induced by hypoxia, and these two
molecules appear to have a synergistic effect on basement membrane degradation [109]. The
inhibitors of MMPs are called tissue inhibitors of metalloproteinases (TIMPs), which are
comprised of TIMP-1, TIMP-2, TIMP-3, and TIMP-4. The interactions between these proteas‐
es and their inhibitors play important roles in cell morphogenesis, angiogenesis, tissue re‐
modeling, tissue repair, tumor metastasis, cirrhosis, and arthritis. After breakdown of the
basement membrane, endothelial cells proliferate and migrate toward the tumor cells ex‐
pressing pro-angiogenic compounds. The activation of endothelial cells results in increased
expression of cell adhesion receptors, such as integrins ανβ3 and α5β1, and in increased cell
survival, proliferation, and migration responses. In addition to migration of endothelial
cells, migration of pericytes is an important part of tumor vessel formation. Platelet-derived
growth factor secretion by activated endothelial cells recruits pericytes to the site of newly
sprouting vessels and aids in establishing a new basement membrane [110].
The discovery of hypoxia inducible factor-1 (HIF-1) and the observation that hypoxia-in‐
duced HIF-1α expression in pseudopalisading cells, in tumoral necrotic areas, was concomi‐
tant with the expression of one of its target genes, VEGF, established a biological link
between hypoxia and angiogenesis [111]. The most potent activator of angiogenic mecha‐
nisms in brain tumors is tissue hypoxia. One well-studied pathway is the HIF-1/VEGF-A
pathway, which leads to endothelial cell proliferation and migration. HIF is a heterodimeric
DNA-binding complex composed of two basic helix-loop-helix proteins of the PAS family
(PER, AHR, ARNT and SIM family): the constitutive HIF-1b and one of either hypoxia-indu‐
cible a-subunits, HIF-1a or HIF-2a. In hypoxia, the a/b heterodimer binds to a core pentanu‐
cleotide sequence (RCGTG) in the hypoxia response elements (HREs) of target genes. The
hypoxic microenvironment (1–2% O2) caused by the increased oxygen consumption of hy‐
perplasia and/or hypertrophy and the decreased oxygen delivery due to the increase in dif‐
fusion distance was assumed to contribute to the angiogenic switch. An important link
between hypoxia and angiogenesis was the discovery that the expression of the potent vas‐
cular endothelial growth factor was induced by hypoxia [112]. VEGF, which regulates tumor
edema and blood vessel formation, is an example of a gene regulated by an HIF-1 though an
HRE. Angiogenesis is essential for development, wound healing, tissue or organ regenera‐
tion, but it is also part of pathological processes, such as cancer and certain retinopathies. It
is an intricate multistep and temporally ordered process that involves a great number of
genes, modifiers and pathways. Many of these genes are directly induced by HIF-1a, such as
nitric oxide synthases, angiogenic and vascular growth factors and genes regulating matrix
metabolism (urokinasetype plasminogen activator receptor; uPAR) [113]. Immunohisto‐
chemical expression of HIF-1α clearly correlated with the degree of glioma malignancies
and predicted survival among patients with malignant gliomas and the degree of necrosis
on MRI. In a recent study, has been demonstrated that SN38, the active metabolite of CPT11,
exhibited an antiangiogenic effect. SN38 inhibited HIF-1α and VEGF mRNA and protein ex‐
pression of glioma cells in a dose- and time-dependent manner [114]. Metronomic CPT11
treatment of gliomas exhibited growth inhibitory effects without systemic toxicity, that is,
through comparison of body weight loss that was not observed by conventional CPT11
treatment. Tumor tissues treated with metronomic CPT11 exhibited decreased expression of
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HIF-1α protein and pimonidazole expression, which were indicative of areas of hypoxia by
immunohistochemistry.
4.1. Mediators of glioma angiogenesis
Glioma angiogenesis is mediated by the release of angiogenic cytokines by the tumor cells.
Numerous, different cytokines have been identified so far which are able to induce angio‐
genesis (Figure 1). This cytokine production is either the result of overexpressing angiogenic
factors through genetic alterations or is triggered by hypoxia.
Figure 1. Representation of angiogenesis mediators in gliomas.
In the phosphatidylinositol-30 kinase (PI3K)/Akt and Ras/mitogen-activated protein kinase
(MAPK) converge many angiogenic growth factors, including vascular endothelial growth
factor (VEGF). These pathways modulate important cellular processes in angiogenesis, in‐
cluding endothelial cell proliferation, survival, migration, invasion, tube formation and ex‐
tracellular matrix degradation.
CXCR = C-X-C chemokine receptor, CYR6.1 = cysteine-rich angiogenic inducer 61, CTGF =
connective tissue growth factor, EGF = epidermal growth factor, FGF = fibroblast growth
factor, HGF = hepatocyte growth factor, IL-6 = interleukin-6, IL-8 = interleukin-8, MMP =
matrix metalloproteinases, PDGF = platelet-derived growth factor, PI3K = PI3 kinase, SF =
scatter factor, TGF-a = transforming growth factor-alpha, TGF-ß = transforming growth fac‐
tor-beta.
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4.1.1. VEGF, VEGF-receptors and VEGF pathway
The VEGF family of growth factors and their receptors are the most important mediators of
glioma angiogenesis. The VEGF family includes six glycoproteins referred to as VEGF-A,
VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental growth factor. The VEGF acts as a major
vascular permeability factor and as a mitogen/survival promoter for endothelial cells [115,
116]. VEGF-A and its receptors are the best characterized signaling pathway in angiogenesis
and binds to two receptor tyrosine kinases (RTK) – VEGFR-1 (Flt-1) and VEGFR-2 (KDR,
Flk-1) [117]. It is generally agreed that VEGFR-2 is the major receptor mediating the mito‐
genic, angiogenic and permeability-enhancing effects of VEGF-A. Recent evidence has sug‐
gested that VEGFR-1 participates in haematopoiesis and in the recruitment of monocytes
and other bone marrow derived cells to promote tumor angiogenesis [118]. In addition,
VEGFR-1 is involved in the activation of MMPs associated with matrix degradation and in
the production of growth factors from endothelial cells. VEGF-A gene expression is up-regu‐
lated by hypoxia, mediated by the transcription factor HIF and the product of the von Hip‐
pel–Lindau (VHL) tumor suppressor gene. Other transcription factors capable of up-
regulating VEGF transcription include the ETS-1 proto-oncogene and STAT-3. ETS proteins
activate many genes involved in angiogenesis, including those that regulate VEGFR-1 and
VEGFR-2, integrin b3, some MMPs and urokinase-type plasminogen activator (uPA). ETS-1
is expressed more frequently in GBM being most prominently observed in the glomeruloid
tufts of GBM [119]. VEGF promotes endothelial proliferation via the activation of the MAPK
pathway. VEGF also enhances vascular permeability through the MAPK signaling cascade
by rearranging cadherin/catenin complexes and loosening adhering junctions between en‐
dothelial cells [120]. The VEGF-A is secreted by tumor cells as well as by stromal and in‐
flammatory cells. VEGF-A can be linked in the extracellular matrix through the interaction
with proteoglycans or glycosaminoglycans. The expression of the receptors VEGFR1 and
VEGFR2 is regulated on the endothelial cells in gliomas. VEGF-A activation causes endothe‐
lial cell differentiation into a “tip” cell and a VEGF-A gradient induces “stalk” cell prolifera‐
tion along an opening in the BM in forming of a new vessel sprout [121]. The ligands for
VEGF3 (VEGF-C&D) are expressed by multiple cell types that surround the angiogenic ves‐
sels, suggesting the existence of a novel pro-angiogenic paracrine signaling pathways in
these neoplasms. In addition to transcription factors, VEGF expression is also probably cor‐
relates with many other growth factors and their specific receptors, including transforming
growth factor (TGF)-b, platelet-derived growth factor (PDGF)-B, epidermal growth factor
(EGF), basic fibroblast growth factors (FGF). VEGF promotes endothelial proliferation via
activation of the MAPK pathway. The activation of MAPK/ERK is associated with inhibition
of the Jun-N terminal kinase (JNK) pathway in mediating the anti-apoptotic effect of VEGF.
The PI3K/Akt pathway is of central importance in VEGF signaling. Activated VEGFR-2 me‐
diates the phosphorylation of Akt, which potently inhibits endothelial cell apoptosis by in‐
terfering with various apoptosis signaling pathways. Akt also promotes endothelial cell
migration, and increases the expression of HIF, leading to enhanced VEGF expression [122].
VEGF stimulates endothelial production of urokinase-type plasminogen activator (uPA),
which induces conversion of plasminogen to plasmin, causing the breakdown of ECM com‐
ponents and leading to ECM remodeling [123]. The end result of VEGF signaling in tumors
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is the production of immature, highly permeable blood vessels with subsequent poor main‐
tenance of BBB and parenchymal edema [96, 124]. Alternatively, the angiogenic effect of
VEGF can be mediated through integrins, a1b1, a2b1 and avb3, which promote cell migra‐
tion, proliferation and matrix remodeling.
4.1.2. FGF and FGF receptors
The FGF family of proteins and their receptors are overexpressed in various types of cancer.
Binding of FGF to its receptor causes transphosphorylation and activation of intrinsic tyro‐
sine kinase, which results in signal transduction. Both acidic FGF (aFGF) and basic FGF
(bFGF) are up-regulated in GBM [125] and are responsible for resistance of endothelial cells
to apoptosis. Basic fibroblast growth factor (bFGF) is expressed by vascular cells and, focal‐
ly, by the tumor cells. The receptors for bFGF include FGFR1, expressed by the tumor cells
and the tumor endothelial cells and the FGFR2 expressed only by the tumor cells. The anti-
apoptotic effect of bFGF is mediated by increased expression of Bcl-XL and Bcl-2 via the
MEK-dependent signaling pathway. In addition, bFGF stimulates the expression of VEGFR
in endothelial cells.145 Similar to VEGF, aFGF and bFGF induce endothelial cell prolifera‐
tion and migration. Furthermore, FGF activation leads to remodeling of ECM and degrada‐
tion of the basement membrane by inducing production of plasminogen activator,
collagenase and MMP in endothelial cells [127].
4.1.3. PDGF Family
PDGF-B and platelet-derived growth factor b receptor (PDGFRb) have important roles in
the development and differentiation of the vessel wall [128]. PDGF is a mitogen for multiple
cells of mesenchymal and neuroectodermal origin that acts through the PDGF receptors α
and β. PDGF-B is required for recruitment of pericytes and maturation of the microvascula‐
ture. PDGFR-β is expressed on endothelial cells of astroglial tumors and that PDGF expres‐
sion correlates with astroglial malignancy and angiogenic activity
PDGF contributes indirectly to tumor angiogenesis acting as a potent mitogenic and che‐
motactic  stimulus for angiogenesis  associated stromal cells,  such as smooth muscle cells
or pericytes. However, PDGF’s effects on angiogenesis are mediated partly by VEGF. The
angiogenic effects of PDGF are mediated through PI3K/Akt, MAPK/ERK and STAT3 sig‐
nalling [129].
4.1.4. Molecules of the inflammatory cascade
Molecules of the inflammatory cascade act indirectly on angiogenesis via modulating ex‐
pression of direct angiogenic factors. Interleukin-8 (IL-8) is a potent chemoattractant. But re‐
cent data suggest that it has a critical role in glial tumor angiogenesis and progression. High
expression levels of PGES-1 (Prostaglandine E 1 Sinthase) and IL-8 in malignant gliomas
cells and microglial cells, strongly correlated with grading tumor, are been demonstrated
[130]. IL-8 expression is first observed in low grade astrocytoma in perivascular tumor areas
expressing inflammatory cytokines. In malignant gliomas, IL-8 further localizes in oxygen-
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deprived cells surrounding necrosis. IL-8, however, stimulates angiogenesis via the interac‐
tion with the CXC chemokine receptor 1 (CXCR1), CXCR2 and Duffy antigen receptor for
cytokines (DARC). DARC expression has been detected on tumour-associated endothelial
cells, whereas CXCR1 and CXCR2 are found on infiltrating leukocytes near blood vessels.
Macrophages are known to produce high levels of IL-8, which has a tumorigenic activity, by
inducing tumor growth and angiogenesis; IL-8 is an inflammatory chemoattractant respond‐
ing to the tumor microenvironment. Tumor pseudopalisading cells secrete HIF which indu‐
ces IL-8 secretion. On the basis of preliminary results, the role of IL-8 as crucial angiogenesis
mediator within HIF-1α pathway and crosstalk between hypoxia-induced high levels of
HIF-1α and VEGF expression has been demonstrated.
The cyclooxygenase isoforms (COX-1 and COX-2) catalyze the synthesis of prostaglandins
from arachidonic acid. While COX-1 is ubiquitously expressed in a wide range of tissues,
COX-2 is cytokine inducible. COX-2 is expressed in human glioma cells where its expression
correlates with malignancy, being highest in glioblastoma. The anti-angiogenic efficacy of
COX-2 inhibitors is currently explained first by downregulation of VEGF, which results in
blocking of endothelial cell proliferation and induction of endothelial cell apoptosis and sec‐
ond by inhibition of integrin function and signaling.
Tumor necrosis factor-α (TNF-α) is a potent proinflammatory cytokine with a quite complex
role in endothelial cell survival and migration. It has impact on endothelial cell survival and
migration via its TNF-receptor 1 and 2 which are both expressed on endothelial cells.
Membrane type 1-matrix metalloproteinase (MT1-MMP) expressed by the tip cell of an en‐
dothelial sprout opens up the surrounding matrix and is only later down-regulated when
stalk cells come into contact with pericytes. Re-established contact between endothelial cells
and pericytes induces expression of tissue inhibitor of metalloproteinases-2 (TIMP-2) in en‐
dothelial cells and TIMP-3 in pericytes in switching off the proteolytic phenotype in endo‐
thelial cells [131]. MT1-MMPs on the endothelial cell surface are also required for the
subsequent step in the angiogenesis cascade of tube formation by playing a role in endothe‐
lial intracellular vacuole and lumen formation. The vessel lumen is tightly sealed by adjoin‐
ing endothelial cells held together by tight and adherens junctions. A basement membrane is
then produced by endothelial cells in cooperation with surrounding cells in providing struc‐
tural support and maintaining endothelial cell quiescence. The BM is built up of scaffolding
laminins and essential components such as collagen IV, perlecan, nidogens, and collagen
XVIII [132-133]. During the maturation of new capillaries, pruning of excess or unneeded
vessels for optimal perfusion is proposed to represent an adjustment to oxygen surplus
while the surrounding ECM exerts mechanical strain providing traction and orientation for
angiogenic microvessels [134].
Many other proangiogenic factors are upregulated in gliomas and this aspect might explain
the failure of many actual antiangiogenic therapeutic strategies in gliomas management.
TGF-b and its receptors are highly expressed in malignant gliomas, especially in areas of
vascular hyperplasia and around necrotic regions. In glioma cells, the angiogenic effect of
TGF-b is probably mediated through the enhanced expression of VEGF. TGF-b also pro‐
motes angiogenesis via the integrin signaling pathway. TGF-b upregulates expression of
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ανβ3 integrin that, in turn, binds to MMP-2, which leads to degradation of the ECM and en‐
hanced endothelial cell invasion [135]. An important role has absolved by IL-1beta, IL-6,
TNF-alpha and stromal-cell-derived factor (SDF)-1 alpha [46].
5. Microglia
Glioma tissues as obtained by surgical resection contain also a considerable amount of non-
transformed cells. The majority of these cells are tumor-associated macrophages (TAMs)
[136-137]. Resident macrophages of the brain are termed microglia. These cells invade the
brain early in development and differentiate into so-called resident, ramified microglia.
These tumor-associated microglia displayed an ameboid morphology similar to that descri‐
bed in other pathologies. Since microglia share many properties with macrophages found in
non-neuronal tissues including the blood, it was possible that glioma-associated microglia
could be recruited de novo from the microglial population resident in the brain, or alterna‐
tively, migrate into brain tumors from the periphery. To address this question, Badie and
Schartner [138] used CD45 labeling of cells in rodent tumor models to distinguish brain mi‐
croglia (CD45 low) from peripheral macrophages (CD45 high). They used CD11b/c as a gen‐
eral marker for macrophages and sorted the CD11b/c2 positive cells into two populations
showing high and low CD45 expression. From this, they concluded that the macrophages
are primarily found within tumors, while microglia was detected in all brain tissue. Thus,
the precise origin of tumor microglia remains to be determined. Regardless of origin, we can
define any glioma-associated monocytic cell with macrophage characteristics as a tumor-as‐
sociated microglia. Candidate chemoattractants of tumor-associated microglia include mon‐
ocyte chemotactic protein-3(MCP-3), colony-stimulating factor 1 (CSF-1), granulocyte-
colony stimulatory factor (G-CSF), and hepathocyte growth factor/scatter factor: each of
these has been shown to be released by gliomas and microglia are known to express recep‐
tors for these chemoattractant growth factors [139-140].
TAMs promote cancer progression through several mechanisms, including promotion of an‐
giogenesis, induction of tumour growth, and enhancement of tumour cell migration and in‐
vasion. The hypoxic stress in the tumour mass leads to the expression of inflammatory
molecules, which promote the recruitment of macrophages followed by conversion to the
M2 phenotype. TAMs are capable to modulate and induce neovascularization and functions
related to stroma formation. When TAMs are activated, in response to specific stimuli, these
cells can express a repertoire of substances that promote angiogenesis. Growth factors such
as acidic fibroblasts growth factor (aFGF/FGF1), basic fibroblasts growth factor (bFGF/
FGF2), vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor
(GM-CSF), transforming growth factor-α, insulin-like growth factor-1, platelet derived
growth factor (PDGF), tumour growth factor-β (TGF-β) and other monokines (e.g. tumour
necrosis factor-α (TNF-α), interleukin-1, interleukin-6, interleukin-8, substance P, prosta‐
glandins, interferons and thrombospondin which are released by tumour cells leads to the
activation of macrophages and have the capability to influence the angiogenic process [141].
Therefore, macrophages recruited in situ represent an indirect pathway of amplification of
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angiogenesis, in concert with angiogenic molecules directly produced by tumor cells. In ex‐
perimental in vitro studies, glioma cell lines seem produce high levels of a monocyte-macro‐
phages-derived cytokine, IL-8, that induces formation of tube-like structures by human
microvascular endothelial cells [142]. We previously demonstrated significant increase in
IL-8 protein level in astrocytic cultures treated with PGE2. The ability of PGE2 to increase
IL-8 expression in glioma cells has a significant biological impact on tumorigenesis, as
shown by increased growth and reduced apoptosis in PGE2-treated cells [143]. Macrophag‐
es can exert a dual influence on blood vessel formation. On the one hand macrophages pro‐
duce proangiogenic molecules on the other hand they can express anti-angiogenic molecules
and damage the integrity of blood vessels. In general the pro-angiogenic functions of TAMs
prevail [144].
Angiogenesis is also facilitated by TAM-derived proteases released in tumours, as extracel‐
lular proteolysis is an absolute requirement for new blood vessel formation. Macrophages
can express proteases to release a number of pro-angiogenic molecules bound to heparan
sulfate in proteoglycans, and fragment of fibrin and collagen, which facilitate angiogenesis.
Among these, matrix metalloproteases (MMPs 1, 2, 3, 9 and 12), plasmin, urokinase plasmi‐
nogen activator and receptor are the prominent ones which promotes tumour directed an‐
giogenesis. MMPs are a family of matrix degrading enzymes including collagenase
(MMP-1), gelatinase A (MMP-2), stromelysin (MMP-3), matrilysin (MMP-7), gelatinase B
(MMP-9), and other MMPs. TAMs have been reported to correlate with the metastatic po‐
tential of a variety of human cancers, and they have also been shown to be a major source of
MMP-9. In addition, urokinase-type plasminogen activator is a serine protease synthesized
by TAMs in various human tumour types [145]. TAMs were shown to express CXCL8,
which like VEGF, binds heparin in the ECM and stimulate angiogenesis [146]. Thus TAMs
have the capacity to affect each phase of the angiogenic process, including degradation of
the extracellular matrix, endothelial cell proliferation and endothelial cell migration. TAMs
can also secrete cysteine-type lysosomal proteases and a wide variety of growth factors that
can stimulate cancer growth.
New blood vessels in tumours are usually disorganized and prone to collapse, resulting in
areas of inadequate perfusion and hypoxia (low oxygen tension). Additionally, rapid tu‐
mour cell proliferation in some areas may outpace the rate of new blood vessel growth,
causing hypoxic areas to form [147]. The level of TAMs in tumours appears to be affected by
hypoxia, a trait commonly found in these tissues. TAM numbers are generally higher in tu‐
mours containing high overall levels of hypoxia, as seen in primary human breast carcino‐
mas and various animal tumours. Hypoxic tumours secrete higher amounts of
chemoattractants and/or other factors that enhance monocyte attachment to and migration
through the tumour vasculature. Once targeted to hypoxic sites, TAM functions are greatly
affected by hypoxia-related factors. Because macrophages are phagocytes, they may also be
attracted to hypoxic, perinecrotic areas along a trail of necrotic debris emanating from dead
cells. Hypoxia also entraps TAMs by decreasing their mobility in a number of ways. One
such approach involves the hypoxic up-regulation of the enzyme mitogen-activated protein
kinase phosphatase (MKP-1) by macrophages. This is important because various chemoat‐
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tractant receptors, including those for CCL2, VEGF, and endothelin 2, stimulate cell migra‐
tion by phosphorylating the signaling enzymes MEK, ERK1/2, and p38 MAPK. Up-
regulated MKP-1 rapidly dephosphorylates these molecules in TAMs, thus terminating the
chemotactic response of TAMs to these chemokines [148]. Hypoxia also inhibits macrophage
expression of the chemokine receptors CCR2 and CCR5 [149], further helping to immobilize
TAMs. Hypoxia also induces a profound change in the phenotype of macrophages, promot‐
ing increased expression of a wide range of genes.
This is brought about by the hypoxic up-regulation of such transcription factors as hypoxia-
inducible factors, HIF-1α and HIF-2α. TAMs respond to hypoxia by up-regulating a broad
array of genes encoding proteins that promote the proliferation, invasion, and metastasis of
tumour cells as well as tumour angiogenesis. Genes coding for M-CSF, a growth factor that
promotes the survival and differentiation of macrophages, is over expressed in some human
tumours, and elevated M-CSF levels correlate with high TAM numbers and poor prognosis
[150]. Hypoxic macrophages are also likely to promote the invasive and/or metastatic behav‐
ior of tumour cells by releasing such pro-invasive factors as macrophage inhibitory factor
[151]. Macrophage inhibitory factor is known to modulate the activities of a number of cell
types in tumours, including stimulation of tumour cell motility [152]. This may involve indi‐
rect effects such as macrophage inhibitory factor-stimulated release of matrix metalloprotei‐
nase 9, which in turn degrades components of the basement membrane and extracellular
matrix, thereby increasing the motility of tumour cells.
In a cultured mouse brain slice model, the invasion and growth of glioma cells was com‐
pared between normal and microglia-depleted slices. Glioma cell invasion was significantly
reduced in microglia depleted slices relative to control slices [153]. The impact of microglia
on glioma migration might relate to the production of membrane type 1 metalloprotease
(MT1-MMP or MMP-14) that are produced by microglia in response to soluble factors re‐
leased from glioma cells. Glioma cells also release metalloproteases 2 that is fully activated
by MT1-MMP released from microglia. The consequent degradation of the extracellular ma‐
trix has been postulated to enhance the invasion of glioma cells into the brain parenchyma.
The importance of microglia for glioma growth was further substantiated by studying ani‐
mals in which microglia was depleted. The microglia-depletion in vivo was achieved by us‐
ing the CD11b-HSVTK mouse model. Seven days after intracerebral glioma inoculation,
ganciclovir (a specific substrate for the viral thymidine kinase HSVTK) was infused via
mini-pumps into the tumor area for a further 7 days. To restrict the effect of ganciclovir on
the intrinsic microglial population, the mice were irradiated before bone marrow transplant‐
ed with wild-type monocytes. The ganciclovir treatment led to a considerable depletion of
microglia and to an 80% reduction in glioma volume [153].
CD68 is a monoclonal mouse antibody that labels human monocytes and macrophages. The
antigen recognized by CD68 is absent from resting microglia but readily detectable in phag‐
ocytic microglia, perivascular cells and brain macrophages. In a recent study, the presence of
CD68 positive cells neighboring of neoplastic cells, contiguous to necrotic and hypoxic areas
within neoplastic tissue has been evidenced. The presence of TAMs that passed through ves‐
sel wall also in low-grade astrocytomas was, also, observed [154]. In anaplastic cases, neo‐
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plastic cells seem to be guided towards microglia. These data, can reinforced the hypothesis
that macrophage infiltration could be closely associated with neovascularization and malig‐
nancy in human gliomas. Matrix metalloprotease activity is also regulated by the CX3CL1/
CX3CR1 signaling pathway. For example, matrix metalloproteases 2, 9, and 14 are upregu‐
lated in microglia following activation of CX3CL1/CX3CR1signaling. Notably, CX3CR1 is
upregulated in glioma associated microglia [155] and polymorphisms in the chemokine re‐
ceptor CX3CR1 have been associated with prognosis among patients with glioma. The com‐
mon CX3CR1 allele (termed V249I) was a favorable prognostic factor. Patients who had only
this CX3CR1 allele had a more than 1.5 longer mean survival time. This common allele was
associated with reduced microglial cell infiltration in primary tumor biopsies [155].
In a previous study has been demonstrated, in a series of GBM, the presence of laminin, fi‐
bronectin and type IV collagen in hyper-plastic vessels, in and around vascular channel, in
vascular walls and at level of BM associated with endothelial glomerulus-like proliferations
[83]. Laminin within the BM can bind to both endothelial cells and tumor cells and is in‐
volved in angiogenesis and tumor growth. We can hypothesized that in pilocytic astrocyto‐
ma, the ECM integrity cause a reduced macrophagic/microglial migration. In this view, an
incompetent control of interactions occurs between microglial adhesive molecules and ECM
substrates. In low-grade astrocytomas is achievable that low macrophage/microglial recruit‐
ment is also correlated with a lower vascular neo-angiogenesis. This relationship may influ‐
ence microglial morphology, blocking microglial migration and phagocytosis [154]. To
support these findings, a recent study showed an increase of CD68 positive cells which cor‐
related with trends toward worse event-free survival [156].
6. Therapeutic strategies for malignant gliomas
The treatment of brain cancer is one of the most difficult challenge in neurosurgery and on‐
cology. Malignant gliomas involve, in their progression, multiple aberrant signaling path‐
ways and the blood-brain barrier (BBB) restricts the delivery of many chemotherapeutic
agents. Current conventional treatments protocols include maximally safe surgical resection
followed by fractionated radiation therapy of the tumor and surrounding brain parenchyma
and systemic chemotherapy. However, radiation therapy is limited to a largely palliative
role, and chemotherapy has provided only a modest benefit in clinical outcome. There are
several factors underlying the disappointing results in brain cancer therapeutics including
limited tumor cell drug uptake, intracellular drug metabolism, inherent tumor sensitivity to
chemotherapy, and cellular mechanisms of resistance. The BBB protects the brain from tox‐
ins and fluctuations in systemic chemical concentrations, but it also excludes many thera‐
peutic agents. Multimodal therapeutic approaches and molecular-based targeted therapies
are modern and complex strategies potentially very efficacious and applicable to up-regu‐
late the selectivity of therapeutic effects and down-regulate systemic toxicity and side effect
toward peritumoral and safe brain tissue. Developments in molecular biology have led to a
clearer understanding of the mechanisms of tumor development and resistance to therapy.
As a results, new treatment strategies are emerging that target steps in the molecular patho‐
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genesis of brain gliomas. An optimal realization of a system that overcomes the problems
associated with developing effective brain tumor treatments requires the identification of
neoplastic markers, and understanding their evolution over time, and the development of
technology for the biomarker-targeted delivery of multiple therapeutic agents, and for the
simultaneous capability of avoiding biological and biophysical barriers. In this complex phe‐
nomenon it is fundamental to improve specific selective drugs delivery systems: in this way,
drugs, antisense oligonucleotides (AONs), small interference RNAs, engineered monoclonal
antibodies and other therapeutic molecules may diffuse into CNS overcoming the BBB.
Glioma gene expression and its development during gliomagenesis may help to better un‐
derstand the role of important molecules involved in tumor-safe brain parenchyma relation‐
ships. These molecules, such as ECM proteases, cell adhesion molecules, and their related
signaling pathways, show an important role in glioma cell migration and invasion and
could selectively attack to inhibit the glioma invasive rim. Various small molecule inhibitors
and antibodies has been developed, and is continuing to be developed, to target key compo‐
nents of the signal transduction machinery, with a particular focus on growth factors and
their corresponding receptors and canonical downstream signal transduction intermediates.
Many of these inhibitors have potential for the treatment of glioblastoma. Testing some of
these inhibitors, as well as using genetic approaches to untangling these signaling networks
in well-designed model systems (including both highly representative xenograft models and
mouse genetic models), is beginning to provide an emerging picture of the targetable molec‐
ular phenotype of glioblastoma.
Angiogenesis is tightly correlated with the histological grading and prognosis of gliomas.
Glioma vasculature is structurally and functionally abnormal, leading to vasogenic edema,
increased interstitial pressure, and heterogeneous delivery of oxygen and drugs. VEGF is
the key factor implicated in the angiogenesis of gliomas. It acts as a major vascular permea‐
bility factor and as a mitogen/survival promoter for endothelial cells. VEGF expression is
stimulated by hypoxia, acidosis, and many growth factors (EGFR, PDGFR, HGFR, CKit, in‐
sulin-like growth factor receptor), and their downstream signaling pathways (PI3K–Akt,
Ras–MAPK) are commonly activated in gliomas. However, many other proangiogenic fac‐
tors are upregulated in gliomas, and this might explain how gliomas may escape a specific
antiangiogenic therapy. Antiangiogenic therapy is able to normalize the structure and func‐
tion of abnormal neovasculature [96]. The normalization hypothesis states that antiangio‐
genic therapies may augment the effects of chemotherapy and radiotherapy by normalizing
tumor vessels. Furthermore, normalizing tumor vessels might also reduce hypoxia, and thus
make the tumor cells more sensitive to chemotherapy and radiation therapy [96].
6.1. Molecular targeted therapy
Elevated expression or mutation of receptors and intracellular downstream effectors has
been demonstrated in gliomas. These pathways are controlled by several growth factors
linked to tyrosine kinase. Specific targeting of these signaling pathways that lead to altered
cellular proliferation and cell migration and invasion could provide new molecularly target‐
ed options for glioma treatment. The introduction of molecularly targeted agents is one of
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the most significant advances in cancer therapy in recent years. Targeted therapies block ac‐
tivation of oncogenic pathways, either at the ligand–receptor interaction level or by inhibit‐
ing downstream signal transduction pathways, thereby inhibiting growth and progression
of cancer. Because of their specificity, targeted therapies should theoretically have better ef‐
ficacy and safety profiles than systemic cytotoxic chemotherapy or radiotherapy. The main
rationale for using antiangiogenic therapies in glioblastoma is to normalize the vasculature,
restoring the selective permeability of the blood-brain barrier.
6.1.1. VEGF, VEGF-receptors and VEGF pathway
VEGF-A is a member of the VEGF family that acts as a key proangiogenic factor because of
its specificity to endothelial cells and the multitude of responses that it can elicit. These in‐
clude ECM degradation, endothelial cell proliferation, migration and tube formation, and
expression of other proangiogenic factors, such as urokinase-type plasminogen activator,
plasminogen activator inhibitor-1, urokinase-type plasminogen activator receptor, and ma‐
trix metalloproteinase-1. Overexpression of VEGF-A occurs in response to hypoxia, PDGF,
EGF, transforming growth factor-h, interleukin-1h, and tumor necrosis factor-a. The best-
studied receptor is VEGFR-2, a potent tyrosine kinase that mediates endothelial cell signal‐
ing through the activation of Ras/Raf/MEK/MAPK, PI3K/AKT/PKB, and protein kinase C
pathways. Has been suggested that blocking VEGF pathways may normalize tumor vascu‐
lature and improve chemotherapy delivery, allowing higher drug concentrations [157].
Several strategies for targeting VEGF have been proposed, such as VEGFR TKI, anti-VEGF-
A and VEGFR-2 monoclonal antibodies, antisense oligonucleotides, and ribozymes. The
best-studied drugs in gliomas have been vatalanib (PTK787/ZK222584), ZD6474, sorafenib
(BAY 43-9006), sunitinib (SU11248), and cediranib (AZD2171). Difficulties include defining
the optimal biological dose of drugs that are rarely toxic, determining the relevance of com‐
binations with cytotoxic chemotherapy and radiotherapy, and elucidating adequate surro‐
gate markers.
Vatalanib is a VEGFR-1 and VEGFR-2 TKI that showed activity in glioma cell lines and xen‐
ograft models [158]. A phase I study of vatalanib, and c-kit in patients with newly diagnosed
GBM receiving radiation, temozolomide, and an enzyme-inducing anti-epileptic drug in or‐
der to determine the MTD of vatalanib in this patient population was evaluated. Vatalanib
was well tolerated with only 2 DLTs (thrombocytopenia and elevated transaminases). Other
grade 3/4 toxicities included leukopenia, lymphopenia, neutropenia, and hand-foot syn‐
drome. Of the 13 patients evaluable for a radiographic response, 2 had a partial response
and 9 had stable disease. Vatalanib significantly increased PlGF and sVEGFR1 in plasma cir‐
culation and decreased sVEGFR2 and sTie2. Vatalanib was well tolerated and this study
demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients.
Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angio‐
genic therapies [159].
ZD6474 is a VEGFR-2 TKI with additional VEGR-3 and EGFR inhibition properties. In vivo
models showed a broader spectrum of action, suggesting an antiangiogenic and anti-VEGFR
preponderant effect [160]. In a glioma xenograft study, ZD6474 decreased tumor volume,
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lowered the tumor cell proliferation index (Ki-67), and increased tumor cell apoptosis. How‐
ever, microvascular density, a typical marker of angiogenic activity, surprisingly increased,
raising doubts on the antiangiogenic effects of the drug [161].
The effect of ZD6474, was also evaluated in combination with either radiotherapy or temo‐
zolomide. ZD6474 in combination with radiotherapy significantly decreased tumour area by
66% compared with controls whereas the combination with temozolomide decreased tu‐
mour area by 74% [162].
Recently, the AEE788, a reversible TK inhibitor that inhibits EGFR and VEGFR, in recurrent
glioblastoma patients, was evaluated [163]. Continuous, once-daily AEE788 was associated
with unacceptable toxicity and minimal activity for the treatment of recurrent glioblastoma.
The study was, therefore, discontinued prematurely.
Cediranib (AZD2171) is a potent, orally available, small-molecule inhibitor of VEGF-recep‐
tor (VEGFR) tyrosine kinase activity that  rapidly normalizes tumor blood vessels  in pa‐
tients with glioblastoma, leading to a clinical improvement in cerebral edema [164]. In a
recent  study,  drug  effects  were  evaluated  over  time  through the  use  of  magnetic  reso‐
nance imaging techniques (including analysis of perfusion, permeability, and relative ves‐
sel  size)  and assessment of  circulating progenitor  cells,  circulating endothelial  cells,  and
plasma levels of several proangiogenic proteins. Results suggest that cediranib leads to a
normalization of vasculature and decreased edema; however, such effects disappear over‐
time,  which is  accompanied by an increase in  circulating basic  fibroblast  growth factor,
stromal  cell-derived  factor-1a,  and  circulating  endothelial  cells.  In  mouse  models,  im‐
provement  in  edema  was  associated  with  increased  survival,  despite  continued  tumor
growth  [165].  The  first  clinical  data  of  the  REGAL  trial  of  cediranib  plus  lomustine
(CCNU) to investigate  whether  preclinical  findings will  translate  into improvements  for
patients with recurrent glioma have been negative [166].
Single-agent sunitinib, an oral small molecule inhibitor of multiple tyrosine kinase receptors,
was evaluated for treatment of patients with recurrent glioblastoma and anaplastic astrocy‐
toma (AA). For AA patients, the most common side effects were fatigue, diarrhea, hand-foot
syndrome, neutropenia, thrombocytopenia, and nausea. In the GBM cohort, the most com‐
mon side effects were fatigue, diarrhea, neutropenia, and thrombocytopenia. Median overall
survival was 12.1 months (AA) and 12.6 months (GBM). Nonetheless, sunitinib did not dem‐
onstrate significant anti-glioma activity in patients with recurrent malignant astrocytic glio‐
mas [167]. Recent preclinical studies suggest that treating GBM with a combination of
targeted chemotherapy and radiotherapy may enhance the anti-tumor effects of both thera‐
pies. In a recent study, have been evaluated the effects of combination therapy in a mouse
gliomamodel that utilizes a PDGF-IRES-Cre-expressing retrovirus to infect adult glial pro‐
genitors in mice carrying conditional deletions of Pten and p53. The addition of sunitinib to
low-dose radiation caused a modest, but significant delay in tumor growth. However, no
significant survival benefit was seen as tumors progressed in 100% of animals. Histological
analysis revealed a reduction in vascular proliferation and a marked increase in brain inva‐
sion. The results showed that the addition of Sunitinib to radiotherapy fails to significantly
alter survival in GBM despite enhancement of the effects of radiation [168].
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In gliomas, despite evidence of activity in preclinical models, clinical development of beva‐
cizumab was delayed initially because of the fear of central nervous system hemorrhage
[169]. Bevacizumab is a monoclonal antibody against VEGF inhibiting angiogenesis by pre‐
venting receptor activation. Phase II clinical trials using bevacizumab in both newly diag‐
nosed and recurrent high-grade glioma showed promising results. Bevacizumab has been
shown to be safe and tolerable in malignant gliomas. In the recurrent disease setting, bevaci‐
zumab alone might be sufficient for a clinical benefit and is currently approved as a single
agent for this indication. In a phase II study was evaluated the efficacy and safety of bevaci‐
zumab in Japanese patients with recurrent malignant glioma. The 6-month progression-free
survival rate in the 29 patients with recurrent glioblastoma was 33.9% and the median pro‐
gression-free survival was 3.3 months. The 1-year survival rate was 34.5% with a median
overall survival of 10.5 months. There were eight responders (all partial responses) giving
an objective response rate of 27.6%. The disease control rate was 79.3% [170].
Norden et al. [171] analyzed the pattern of recurrence in patients treated with bevacizumab
and irinotecan, and their observations suggest that bevacizumab might more efficiently sup‐
press enhancing tumor recurrence than infiltrative tumor growth. A single-institution phase
II trial using the humanized monoclonal VEGF antibody bevacizumab combined with irino‐
tecan in malignant gliomas has been reported [172]. No central nervous system hemorrhag‐
es were observed. The 6-month PFS rates were 30% and 56% in grade 4 and grade 3 gliomas,
respectively, comparing favorably with historical controls. In a similar study, bevacizumab
plus irinotecan in recurrent malignant gliomas improves responses, progression-free surviv‐
al, and overall survival compared with historical data. Karnofsky performance status of at
least 80% was a predictive factor for response and overall survival [173].
In a recent research was evaluated concurrent bevacizumab with hypofractionated stereo‐
tactic radiation therapy (HSRT) for the treatment of recurrent malignant gliomas. Despite
the promising initial response seen with the addition of HSRT to bevacizumab as salvage
treatment for recurrent gliomas, approximately half of patients ultimately still experience
failure within the radiation field. The rate of local failure with the addition of HSRT seems
to be lower than that seen with bevacizumab alone in the salvage setting [174].
Several studies of bevacizumab in combination with metronomic dosing of temozolomide or
etoposide or with daily erlotinib in recurrent glioma patients are ongoing.
6.1.2. Epidermal growth factor receptor
Epidermal growth factor receptor (EGFR, ErbB1, HER1) is a tyrosine kinase receptor that is
abnormally activated in 70% of solid cancers. EGFR overexpression and immunoreactivity
are more common in primary tumors than in secondary glioblastomas. Activation of EGFR
pathways in cancer cells has been linked to increased motility, adhesion, invasion, and pro‐
liferation of tumor cells as well as inhibition of apoptosis and induction of angiogenesis.
The EGFR transmembrane protein comprises three domains: the extracellular domain, the
transmembrane domain, and the cytoplasmic domain, which harbors the tyrosine kinase ac‐
tivity. Ligand binding (amphiregulin, EGF, transforming growth factor TGF-β, decorin, be‐
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tacellulin, epiregulin, neuroregulin) to the extracellular domain of a monomer results in its
homo- or heterodimerization, inducing phosphorylation of the tyrosine kinase domain, acti‐
vating several signaling pathways, in particular: phosphatidylinositol 3’-kinase/Akt/
mammalian target of rapamycin (mTOR), Ras/mitogen-activated protein kinase (MAPK),
phospholipase C (PLC)/protein kinase C (PKC), and (d) c-Src [175]. These activated path‐
ways are involved in several cell biological processes, including cell proliferation, angiogen‐
esis, migration/adhesion, survival, and differentiation. Approximately 50% of glioblastomas
overexpress EGFR and 25% express a constitutively active mutated form of EGFR. This acti‐
vation occurs through several molecular mechanisms: protein overexpression, reported in
~60% of cases; gene amplification, reported in ~40% of cases; truncated transcripts encoding
for a constitutionally active receptor, reported in ~20% (mainly EGFRvIII) of cases; and mu‐
tation of the extracellular domain (15%) [175]. These alterations, which are quite frequently
combined in the same tumor, activate the EGFR downstream signaling pathways, promot‐
ing the oncogenic process. Therefore, several strategies have been developed in order to
block the EGFR signaling pathway, including small molecule tyrosine kinase inhibitors
(TKIs), monoclonal antibodies, toxin-linked conjugates, and vaccine therapies. However,
caution is needed with EGFR inhibitors, because hypoxia and low glucose levels might con‐
vert the cytotoxic effects of EGFR inhibition into a cytoprotective effect.
Two main EGFR small molecule TKIs have been evaluated in gliomas: gefitinib and erloti‐
nib. These small molecules, which are orally delivered, block the ATP pocket of the EGFR
intracellular tyrosine kinase domain and thus inhibit activation of downstream signaling
pathways.
Growth factor pathway expression using epidermal growth factor receptor (EGFR), mutant
EGFR (EGFRvIII), platelet derived growth factor receptor (PDGFR), C-Kit and C-Abl togeth‐
er with phosphatase and tensin homolog (PTEN) expression and downstream activation of
AKT and phosphorylated ribosomal protein S6 (P70S6K) was analysed in 26 primary glioma
cultures treated with the tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib and imatinib.
Response for each culture was compared with the EGFR/PDGFR immunocytochemical
pathway profile using hierarchical cluster analysis (HCA) and principal component analysis
(PCA). Erlotinib response was not strongly associated with high expression of the growth
factor pathway components. Increased EGFR expression was associated with gefitinib re‐
sponse; increased PDGFR-α expression was associated with imatinib response. The results
of this in vitro study suggest gefitinib and imatinib may have therapeutic potential in glio‐
mas with a corresponding growth factor receptor expression profile [176].
Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor that inhib‐
its cell growth and induces apoptosis in human glioma cells. Gefitinib also induces death of
H4 cells with characteristics of the intrinsic apoptotic pathway, including Bax mitochondrial
translocation, mitochondrial outer membrane permeabilization, cytochrome c cytosolic re‐
lease, and caspase-9/caspase-3 activation. Gefitinib caused Bad dephosphorylation, and in‐
creased its binding preference to Bcl-2 and Bcl-xL. The dephosphorylation of Bad in
gefitinib-treated cells was accompanied by reduced intracellular cyclic AMP content and
protein kinase A (PKA) activity. Adenylyl cyclase activator forskolin attenuated, but PKA
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inhibitor H89 augmented, gefitinib-induced Bad dephosphorylation, Bax mitochondrial
translocation, caspase-9/caspase-3 activation, and viability loss. Inactivation of PKA sensi‐
tized H4, T98G, and U87 cells to gefitinib cytotoxicity, Bad dephosphorylation in serine-112,
and caspase-9/caspase-3 activation [177].
In a recent study, the molecular effects of the tyrosine kinase inhibitor gefitinib on the EGFR
signaling pathway in human glioblastoma were investigated. Resected glioblastoma tissues
exhibited high concentrations of gefitinib, 20 times higher than respective plasma. However,
no significant effect on 12 pathway constituents was detected. In contrast, in vitro treatment
of a glioblastoma cell line, BS-153, with endogenous EGFRwt amplification and EGFRvIII
expression resulted not only in dephosphorylation of the EGFR, but also of key regulators in
the pathway such as AKT. Treating established xenografts of the same cell line as an in vivo
model showed dephosphorylation of the EGFR without affecting downstream signal trans‐
ductors, similar to the human glioblastoma. Taken together, gefitinib reaches high concen‐
trations in the tumor tissue and efficiently dephosphorylates its target [178]. A phase II
study was designed to assess the safety and efficacy of gefitinib given with and following
radiation therapy in children newly diagnosed with a poor prognosis brainstem glioma. The
observation that a subset of children with this generally fatal tumor experienced long-term
progression-free survival, coupled with recent observations regarding the molecular fea‐
tures of brainstem gliomas, raises the possibility that prospective molecular characterization
may allow enrichment of treatment responders and improvement in outcome results in fu‐
ture studies of biologically targeted agents [179].
Comparative analysis of tissue obtained from patients before and after the start of treatment
suggested that EGFR phosphorylation and downstream signaling were not markedly inhib‐
ited after treatment was started. Two main mechanisms of resistance to small molecule TKIs
have been proposed. First, Stommel et al. [180] showed that several RTKs could be activated
simultaneously in gliomas maintaining activation of RTKs downstream signaling pathways.
Thus, inhibition of one single activated RTK is insufficient and could be easily bypassed by
other activated RTKs [181]. Second, in addition to RTK activation, growth factor receptor
downstream signaling pathways can be activated through a mutation of ras or PTEN or an
amplification of PI3K, inducing redundant activation of the signaling pathways [182].
Haas-Kogan et al. reported that glioblastoma patients whose tumor overexpressed and am‐
plified EGFR gene had a better tumor response to small TKIs than patients whose glioblasto‐
ma did not have these molecular abnormalities. In addition, these investigators showed that
low phospho-PKB/Akt level is associated with a good tumor response to erlotinib [183].
The combination of EGFR inhibitors with inhibitors of mTOR, a distal target of the growth
factor receptor signaling cascade (temsirolimus, sirolimus, everolimus), is a promising strat‐
egy. It became clear that the mechanisms of sensitivity and resistance in gliomas differ from
other types of tumors, such as lung cancer, in that the sensitivity in gliomas does not seem to
be linked to tyrosine kinase domain mutations. In order to achieve higher dosages than pre‐
viously used in clinical trials, we conducted a phase I trial to determine the maximum toler‐
ated dose (MTD) for the combination of erlotinib and sirolimus for the treatments of
recurrent malignant gliomas. The MTD was determined to be 150 mg daily for erlotinib and
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications72
5 mg daily (after a 15 mg loading dose) for sirolimus. The dose-limiting toxicity s included
rash and mucositis, hypophosphatemia, altered mental status, and neutropenia. The combi‐
nation oferlotinib and sirolimus is difficult to tolerate at dosages higher than previously re‐
ported in phase II trials [184].
Ongoing trials of gefitinib, erlotinib, and other EGFR TKIs, such as lapatinib, as well as fur‐
ther tissue analysis of finished trials, may clarify whether selection of patients based on
EGFR overexpression, EGFRvIII, pAKT, and/or PTEN expression could improve results.
Other attempts to overcome resistance include trials combining EGFR TKI with cytotoxic
chemotherapy and radiotherapy as well as the use of new agents that are capable of inhibit‐
ing EGFRvIII-overexpressing cell lines in vitro, such as HKI-272 (an irreversible EGFR TKI)
and AEE788 [185].
A phase 2 study assessed the efficacy and safety of concurrent radiation therapy (RT) and
temozolomide with pharmacodynamic dose escalation of erlotinib in patients with newly
diagnosed GBM. Twenty-seven patients were treated in this study. Twenty-two (81%) pa‐
tients came off study for progressive disease (18 [67%]) or adverse events (4 [15%]). Eighteen
patients (67%) have died. Median progression-free survival was 2.8 months, and the median
overall survival was 8.6 months. Erlotinib co-administered with RT and temozolomide was
not efficacious and had an unacceptable toxicity [186].
Recently,  an EGFR murine humanized monoclonal  antibody,  cetuximab was developed.
Little is known about the efficacy of cetuximab in glioma patients. Recently, a phase I/II
study combining cetuximab, radiation, and temozolomide was initiated in order to assess
the safety and efficacy of this combination as first-line treatment for primary glioblasto‐
ma patients [187].
6.1.3. Platelet-derived growth factor receptor PDGFR
PDGFs are a growth factor family composed of four different polypeptide chains (PDGF-A,
PDGF-B, PDGF-C, and PDGF-D) that exert their cellular effects through two types of protein
tyrosine kinase receptors: PDGFR-a and PDGFR-h. Ligand binding induces receptor dimeri‐
zation, activation, and autophosphorylation of the tyrosine kinase domain, which results in
activation of several signal transduction pathways, including Ras-MAPK, PI3K, Src family
kinase, signal transducers and activators of transcription factors (Stat), and phospholipase
Cg. Overexpression of PDGF and PDGFR has been shown to play a role in the development
of cancer through autocrine stimulation of cancer cells, development of angiogenesis, and
control of tumor interstitial pressure. Animal gliomagenesis models have suggested that
PDGFR pathways not only play a role in proliferation but also have effects on cell differen‐
tiation through dedifferentiation of mature cells, prevention of glial cell differentiation, and
even promotion of cancer stem cells [188]. Inhibition of PDGFR was correlated with de‐
creased phosphorylated extracellular signal-regulated kinase and pAKT levels, suggesting
inhibition of MAPK and PI3K pathways. PDGFR and PDGF are frequently expressed in
gliomas, particularly in secondary glioblastomas and seems to be associated with a poorer
prognosis.
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Clinical studies using the tyrosine kinase inhibitor, imatinib mesylate, in malignant gliomas,
have shown no major inhibition of tumor growth or extension of survival for patients, un‐
like those in chronic myeloid leukemia and gastrointestinal stromal tumors. Phase I data in
malignant gliomas have suggested that use of enzyme-inducing drugs significantly affects
drug metabolization [189]. However, preliminary phase II results of single-agent imatinib
have found only limited efficacy in unselected patients [189-190].
The effects of imatinib on the PDGFR downstream signaling pathways as well as on other
cellular functions in human glioblastoma cells were studied. Western blot analysis demon‐
strated that imatinib was more effective in inhibiting the activated rather than the quiescent
forms of the target proteins. Furthermore, the imatinib treatment induced the sustained acti‐
vation of extracellular signal-regulated kinase (ERK 1/2) signaling as well as components of
other downstream signaling pathways, such as PI3K/Akt, STAT3 and p38MAPK. Further
analysis indicated that the activation of ERK induced by the imatinib treatment was related
to the S-phase re-entry of the cell cycle in one of the three glioma cells. Imatinib significantly
inhibited cell migration but not cell growth. The combination treatment of imatinib with a
MEK or PI3K inhibitor resulted in significant growth inhibition but did not inhibit cell mi‐
gration beyond the inhibition achieved with the imatinib treatment alone [191. In a recent
study has been demonstrated that long-term culture with imatinib mesylate against PDGFR
and c-Kit (stem cell factor receptor) resulted in reduced cancer stem cell ability in glioblasto‐
ma cells through cell differentiation. Derived from RG glioblastoma cells co-cultured with
imatinib for 3 months, RG-IM cells showed distinct properties of cell cycle distribution and
morphology in addition to significantly decreased ability to form aggregates and colonies in
vitro and tumorigenicity in vivo. Furthermore, decreased expression of stem cell markers,
i.e., CD133, Oct-3/4, nestin, and Bmi1, and increased terminal neural cell markers, GFAP,
Tuj1, etc., were identified in RG-IM at the mRNA level [192]. Conversely, using a combina‐
tion of imatinib and hydroxyurea achieved better results compared with imatinib alone or
historical controls [193]. It has been hypothesized that imatinib potentializes hydroxyurea
cytotoxic effects through a decrease in tumor interstitial pressure (which would increase hy‐
droxyurea delivery to tumor cells) and a decrease in DNA repair secondary to imatinib-in‐
duced reduction of Rad 51 expression. The combination of imatinib, hydroxyurea, and
vatalanib, a VEGFR inhibitor, was well tolerated in a phase I trial and has been suggested as
a possible multitargeted regimen for GBM [194].
Sorafenib is an orally available antiangiogenic agent that inhibits tumor cell growth and pro‐
liferation by blocking the action of intracellular and receptor kinases, including PDGFR,
RAF kinase, VEGFR2, and c-KIT. In human glioblastoma cell lines, sorafenib inhibited pro‐
liferation synergistically in combination with bortezomib, a proteosome inhibitor, and rot‐
tlerin, an experimental inhibitor of protein kinase C[195-196]. A phase II trial found that
first-line TMZ and radiotherapy followed by TMZ plus sorafenib was tolerated by patients
with glioblastoma, although preliminary efficacy data for this regimen were similar to data
for standard therapy [197]. It has been postulated that sorafenib and protracted, daily temo‐
zolomide may provide complementary therapeutic benefit among recurrent GBM patients.
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The conclusions of this study showed that sorafenib can be safely administered with daily
temozolomide with a regimen with limited activity for recurrent GBM [198].
Tandutinib is an orally active inhibitor of PDGFR, FLT3, and c-KIT tyrosine kinase activity.
Although no preclinical data have been reported for tandutinib in glioblastoma, 2 early-
phase trials are assessing tandutinib in recurrent or progressive glioblastoma as monothera‐
py or combined with bevacizumab. In a novel study, targeted PDGFR-A mediated tumor
growth in vitro and in vivo using the tyrosine kinase inhibitor,tandutinib (MLN-518), which
strongly inhibits PDGFR-A has been evaluated. Although PDGFR-A inhibition by this agent
resulted in reduced mouse tumor cell growth and increased apoptosis in vitro, and reduced
tumor cell proliferation in vivo, tandutinib did reduce tumor volume at the doses tested (360
mg/kg) in vivo [199].
6.1.4. P13K and related pathways
Overactivation of the PI3K/AKT/mTOR pathway seems to play a key role in the down‐
stream signaling pathways promoting growth and survival in several types of tumor cells,
including glioma. Activation of such a pathway is triggered by stimulation of growth factor
receptors (including EGFR, PDGFR, fibroblast growth factor receptor, and insulin-like
growth factor-I receptor) and the Ras pathway, leading to activation of PI3K. Activated PIP3
promotes phosphorylation of AKT through translocation near the cell membrane and activa‐
tion of PDK1 and PDK2. pAKT promotes phosphorylation of several downstream effectors,
including MDM2, p21/p27, Bad, FKHR, nuclear factor-nB, caspase-9, glycogen synthase kin‐
ase-3h, and mTOR. mTOR plays a key role in downstream signaling of the PI3K/AKT path‐
way through the regulation of cellular catabolism, anabolism, proliferation, cell cycle
control, autophagy, angiogenesis, and apoptosis.
In vitro studies have suggested that mTOR activity is particularly highly activated in cells
with deficient PTEN function, including glioma cell lines. Alterations of PTEN expression
are frequent in high-grade gliomas, with PTEN mutations being present in 15% to 40% of
primary glioblastomas [200]. Preclinical studies in gliomas have suggested that PTEN-defi‐
cient tumors show enhanced sensitivity to mTOR inhibition; this provided the rationale for
clinical trials of mTOR inhibitors in glioblastomas [201].
Temsirolimus (CCI-779) is a lipid soluble analog of rapamycin that inhibits mTOR by bind‐
ing to FKBP-12, resulting in cell cycle arrest and decreased growth of several human cancer
cell lines. In a mouse model of PDGF-B driven low-grade gliomas the use of CCI-779 dem‐
onstrated dramatic anti-proliferative effect in these tumors [202]. Again, data from other
studies, demonstrated that the blockade of mTOR with CCI-779 resulted in regional apopto‐
sis and conversion in the character of surviving tumor cells from astrocytoma to oligoden‐
droglioma in a mouse model of Akt+KRas-induced GBMs [203]. In a recent research, a
combination of perifosine and CCI-779 to inhibit Akt and mTOR respectively was adopted.
In vivo, perifosine and CCI-779 showed synergy in inhibiting the PI3K/mTOR axis corre‐
sponding with decreased tumor proliferation and induction of apoptosis [204].
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Recently, was reported that the combination of focal RT and mammalian target of rapamy‐
cin (mTOR) inhibition using clinically relevant concentrations of temsirolimus (CCI-779)
prolongs survival in a syngeneic mouse glioma model through additive cytostatic effects. In
vitro, the mTOR inhibitor CCI-779 exerted marked anti-invasive effects, irrespective of the
phosphatase and tensin homolog deleted on chromosome 10 status and counteracted the
proinvasive effect of sublethal irradiation. In this study, the G-protein signaling 4 (RGS4)
was identified as a novel target of mTOR inhibition and a key driver of glioblastoma inva‐
siveness, sensitive to the anti-invasive properties of CCI-779 [205]. A phase II study of tem‐
sirolimus was conducted in children and adolescents with high-grade glioma,
neuroblastoma or rhabdomyosarcoma. Temsirolimus administered weekly at the dose of 75
mg/m(2) did not meet the primary objective efficacy threshold in children with high-grade
glioma, neuroblastoma or rhabdomyosarcoma; however, meaningful prolonged stable dis‐
ease merits further evaluation in combination therapy [206].
Prompted by in vitro evidence of synergism between mTOR inhibitors and EGFR TKI, ongo‐
ing clinical research is concentrating efforts on such combinations, including trials of temsir‐
olimus, everolimus (RAD001), or sirolimus (rapamycin) combined with gefitinib, erlotinib,
or AEE788. A phase I study combining gefitinib and sirolimus in malignant gliomas found
no significant pharmacokinetic interaction between the two drugs. Preliminary results of a
study using gefitinib and everolimus in unselected recurrent glioblastoma patients were re‐
cently presented. Using modified radiographic criteria, responses were found in 31% of pa‐
tients, including partial and minor responses. However, median OS and PFS were not
different from historical controls [207].
Enzastaurin suppress proliferation and induced apoptosis via a caspase-dependent mecha‐
nism in glioblastoma cells in vitro and inhibited growth of human glioblastoma xenografts,
which was accompanied by decreased phosphorylation of downstream signaling molecules,
including GSK-3b [208]. Enzastaurin is a potent a PKC/PI3K/AKT inhibitor, that reduces an‐
giogenesis and has direct cytotoxic activity against glioma cells in preclinical studies. In a
novel study, therapy was well tolerated with thrombosis, thrombocytopenia, hemorrhage,
and elevated alanine aminotransferase as the most commonly observed drug-associated
grade 3 or higher toxicities. The 6-month PFS was 7% for patients with glioblastoma and
16% for patients with anaplastic glioma. Enzastaurin showed, an anti-glioma activity in pa‐
tients with recurrent high-grade glioma, but does not appear to have enough single-agent
activity to be useful as monotherapy [209].
A recent study was conducted in patients with recurrent glioblastoma or newly diagnosed
disease that was not treatable with standard (chemo)radiotherapy. In this phase 1 research,
the safety and recommended dose of the oral protein kinase C-beta inhibitor (anti-angiogen‐
ic) enzastaurin in combination with single-agent temozolomide, was evaluated. The recom‐
mended dose for enzastaurin in combination with standard 4-weekly temozolomide is
therefore 500 mg OD. Temozolomide did not appear to effect enzastaurin exposures at the
250 mg or 500 mg OD dose levels [210].
In vivo models showed that enzastaurin combined with radiotherapy synergistically re‐
duced tumor volume, radiation-induced satellite tumor formation, upregulation of VEGF
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expression, neovascularization, and GSK-3b phosphorylation [211]. An open-label, single-
arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT)
to treat glioblastoma multiforme (GBM) and gliosarcoma was reported. Progression-free
survival (PFS), toxicity, and correlations between efficacy and molecular markers analyzed
from tumor tissue samples were also evaluated. The treatment regimen was well tolerated.
Overall survival (median, 74 weeks) and progression-free survival (median, 36 weeks) re‐
sults from the current trial were comparable to those from a prior phase II study using erlo‐
tinib and were significantly better than those from 2 other previous studies that used
thalidomide or cis-retinoic acid, all in combination with temozolomide plus RT [212].
In a phase II study of enzastaurin in patients with recurrent heavily pretreated glioblastoma,
an interim analysis showed that objective radiographic responses occurred in ~20% of pa‐
tients. The subsequent phase III trial comparing lomustine and enzastaurin at first or second
recurrence was the firstphase III trial to evaluate a targeted therapy for recurrent glioblasto‐
ma. However, a planned interim analysis found that enzastaurin treatment did not signifi‐
cantly increase PFS, leading to enrolment being halted [213].
6.1.5. SRC and SRC-family kinases
SRC and SFKs are frequently activated in glioblastoma cell lines and patient samples. SRC
and SFKs are promiscuous regulators of multiple signaling pathways regulating cell growth,
proliferation, adhesion, migration, and invasion, which are important processes in tumor in‐
vasion and metastasis. In particular, SFKs mediate signaling from growth factor receptors
that are commonly overexpressed in GBM. Recently, SRC and FYN (an SFK) were shown to
mediate oncogenic EGFR and EGFRvIII signaling in a rodent GBM model [214].
Dasatinib is a potent inhibitor of SRC and SFK tyrosine kinase activity. Preclinical studies in
a wide variety of solid tumor cell lines, including prostate, breast and glioma, have shown
that dasatinib acts as a cytostatic agent, inhibiting the processes of cell proliferation, inva‐
sion and metastasis. Dasatinib also inhibits the activity of osteoclasts, which have a major
role in the development of metastatic bone lesions. Dasatinib also has inhibitory activity
against c-KIT and PDGFR.
In GBM cells, dasatinib inhibited migration and induced autophagic cell death, and autoph‐
agy was increased by combining dasatinib with TMZ [214-215]. In vivo, dasatinib inhibited
invasion, promoted tumor regression, induced apoptosis in EGFRvIII-expressing glioblasto‐
mas, and enhanced the activity of anti-EGFR antibodies.19 Recently, it has been showed that
dasatinib interacts synergistically with JSI-124, an STAT3/JAK pathway inhibitor. Depletion
of Src and STAT3 by siRNA inhibits cell proliferation and migration, suggesting that Src and
STA3 play a key role in these cellular responses [216].
Recently the efficacy of dasatinib, in patients with recurrent GBM after bevacizumab failure,
was explored. Adult patients were treated with dasatinib 70-100 mg twice daily in combina‐
tion with bevacizumab (n = 14). Of the thirteen evaluable patients, none had a complete or
partial response and only one patient had stable disease after an 8 week interval. Median
progression-free survival (PFS) was 28 days. Median overall survival was 78 days. The
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study demonstrated that Dasatinib in conjunction with bevacizumab does not appear to
have activity in patients with recurrent, heavily pretreated GBM [217].
NVP-AEW541is an inhibitor of insulin-like growth factor-I receptor (IGF-IR) kinase activity
on growth and signaling in a panel of glioma cell lines. NVP-AEW541 blocked phosphoryla‐
tion of IGF-IR in a dose- and time-dependent manner and inhibited proliferation and clono‐
genicity. NVP-AEW541 also induced loss of mitochondrial membrane potential and release
of cytochrome c and apoptosis-inducing factor (AIF) from mitochondria. Combined treat‐
ment with dasatinib and NVP-AEW541 induced significantly more apoptosis than either
agent alone in glioma cells, but not non-neoplastic astrocytes, and synergistically inhibited
clonogenic survival. Mechanistic studies indicated that combination of NVP-AEW541 and
dasatinib significantly reduced pERK and pAkt and markedly increased AIF release, Bax oli‐
gomerization and loss of mitochondrial potential compared to each agent alone. These data
indicate that activation of Bax plays a critical role in mediating NVP-AEW541 and dasatinib-
induced apoptosis, and suggest the potential value of combining IGFR inhibition with other
classes of tyrosine kinase inhibitors to potentiate therapeutic efficacy [218].
6.1.6. Integrin inhibitors
Integrins are transmembrane receptors for the ECM that play a role in cell adhesion and cell
migration, namely, in endothelial cell migration, adhesion, and proliferation during angio‐
genesis. Cilengitide is a cyclic arginine– glycine–aspartic acid containing peptide that binds
to and inhibits αvβ3 and αvβ5 integrins, which are specifically involved in angiogenesis.
Cilengitide induces apoptosis in U87 glioma cells by preventing adherence to vitronectin
and tenascin, matrix protein mediators of brain tumor invasion, and growth [219]. In a
phase I study (n = 51) of recurrent high grade glioma patients, cilengitide was well tolerated
and was demonstrated to have some activity. An objective response was observed in five
patients, with two patients demonstrating prolonged complete responses [220]. The most
notable trial to date was a randomized phase II study of cilengitide, which was associated
with a median survival of 10 months in recurrent glioma patients [221].
A novel study was designed to evaluate the efficacy and tumor delivery of cilengitide in pa‐
tients with recurrent glioblastoma. The study accrued 30 patients with recurrent glioblasto‐
ma and, after recovery from surgery, patients were treated with cilengitide (2000 mg i.v.
twice weekly, maximum of 2 years of treatment). The results confirm drug delivery and pos‐
sibly retention in tumor. This study provides evidence that with established dosing, cilengi‐
tide is adequately delivered to the tumor, although as a single agent, efficacy in recurrent
glioblastoma is modest [222].
In Phase I and II GBM trials, cilengitide and the combination of cilengitide with standard
temozolomide  and  radiation  demonstrate  consistent  antitumor  activity  and  a  favorable
safety profile.  Preliminary results of a phase II trial of cilengitide added to radiotherapy
and temozolomide conducted in 52 patients with newly diagnosed glioblastomas suggest‐
ed efficacy in a subgroup of patients, with little or no additional toxicity [223]. A multi‐
center, phase I/IIa study, investigated the efficacy and safety of cilengitide in combination
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with standard chemoradiotherapy in newly diagnosed glioblastoma. Patients were treat‐
ed  with  cilengitide  (500  mg)  administered  twice  weekly  intravenously  in  addition  to
standard radiotherapy with concomitant and adjuvant temozolomide. Treatment was con‐
tinued  until  disease  progression  or  for  up  to  35  weeks.  The  conclusions  demonstrated
that the combination of cilengitide with temozolomide and radiotherapy was well tolerat‐
ed, with no additional toxicity [224]. In a recent study, the mechanisms of cilengitide-in‐
duced cytotoxicity in glioma cells  was evaluated.  The final  data showed that cilengitide
treatment  induced  cell  detachment  in  glioma  cells  plated  on  vitronectin  in  a  dose-de‐
pendent  manner  and  decreased  cell  viability  with  increasing  doses.  Moreover,  the  au‐
thors evidenced that the treatment of glioma cells with cilengitide induced autophagy in
these cells, as demonstrated by puncta LC3-GFP appearance, the increased expression of
LC3II, and increased acidic vacuole formation. Some level of cell apoptosis was observed
in the cilengitide-treated cells only after 48 hours of treatment, following the induction of
autophagy. The pretreatment of the cells  with cilengitide could increase the level of  au‐
tophagy  induced  by  γ-irradiation  and  significantly  decreased  the  viability  of  the  cells
[225].  Nabors  et  al.  examined,  in  a  randomized phase 2  trial,  the  safety and efficacy of
cilengitide when combined with radiation and temozolomide for patients with newly di‐
agnosed glioblastoma multiforme. The authors showed that cilengitide was well tolerated
when  combined  with  standard  chemoradiation  and  may  improve  survival  for  patients
newly diagnosed with glioblastoma multiforme regardless of MGMT methylation status.
The authors concluded that,  from an efficacy and safety standpoint,  future trials  of  this
agent in this population should use the 2000 mg dose [226].
6.2. Antisense strategy
Several approaches are available to manipulate gene expression at the DNA or RNA stage of
protein synthesis. In eukaryotic organism, pre-mRNA is transcribed in the nucleus, introns
are spliced out and then the mature mRNA is exported from the nucleus to cytoplasm. The
small subunit of the ribosome usually starts by binding to one end of the mRNA and is
joined there by other eukaryotic initiation factors, forming the initiation complex. This mul‐
ti-enzymatic complex scans along the mRNA strand until it reaches a start codon, and then
the large subunit of ribosome attaches to the small subunit so that the translation of a pro‐
tein begins. This process, by which the information of a gene is converted into protein, is
referred to as “gene expression”.
Several approaches are available to specifically manipulate gene expression at the DNA or
RNA stage of protein synthesis. An interesting molecular targeting strategy is the introduc‐
tion of single-stranded antisense oligonucleotides, specific molecules involved in cell prolif‐
eration and cell death, to modify gene expression at the translational level. Antisense
oligonucleotides (AONs) are short synthetic single-stranded DNA-sequences, 13-25 nucleo‐
tides long, that bind to and induce the cleavage of homologous stretches of mRNA sequen‐
ces. These result in targeted destruction of mRNA and correction of genetic aberrations.
AONs thus can act as drug molecules and potentially rectify many disease conditions. RNA
and DNA based oligonucleotides are the most prevalent and most practical antisense drugs.
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Interactions of RNA based AONs with target mRNA inhibit gene expression by interfering
with protein translation without necessarily altering mRNA stability. AONs inhibit mRNA
function by several mechanisms including modulation of splicing and inhibiting protein
translation by disrupting ribosome assembly.
Two different and adjunctive antisense-based approaches to modulate gene expression in‐
to cancer cells are RNA interference (RNAi) and ribozymes. RNAi is mainly responsible
for the post-transcriptional regulation of gene expression but is involved in transcription‐
al  regulation.  RNAi  is  a  process  within  living  cells  that  moderates  the  activity  of  their
genes. RNA interference plays a fundamental role in diverse eukaryotic functions includ‐
ing viral  defence,  chromatin  remodeling,  genome rearrangement,  developmental  timing,
brain morphogenesis, and stem cell maintenance. The power of RNAi lies in the key dis‐
covery  that  endogenous  RNAi  gene  silencing  machinery  can  be  hijacked  to  artificially
regulate genes of interest. The selective effect of RNAi on gene expression makes it a val‐
uable research tool, both in cell culture and in living organisms because synthetic double-
stranded RNA (dsRNA) introduced into cells can induce suppression of specific genes of
interest.
Ribozymes are small oligo-ribo-nucleotides which have a specific base sequence with natu‐
ral self-splicing activity. This activity can be directed against virtually any RNA target by
the inclusion of an antisense region into the ribozyme. Some ribozymes have a self-cleavage
catalytic action while other ones are true catalysts and can carry out RNA slicing by transes‐
terification (splicesome) and peptidyl transfer (in ribosomes). A major disadvantage of ribo‐
zymes at present is that, being ribonucleic acids, they are particularly sensitive to nuclease
degradation. Ribozymes are not generally being considered as agents which may be exoge‐
nously administered. Whilst it should be possible to develop nuclease-resistant ribonucleo‐
tide analogues, present strategies employing ribozymes achieve their delivery by genetic
means, in the form of mini-gene constructs. Ribozymes are now utilized to study gene func‐
tion in HIV disease and in cancer research.
6.2.1. Antisense oligonucleotides
The choice  of  the  target  is  crucial  to  the  potential  success  of  the  therapeutic  approach.
The most interesting targets are involved in apoptosis, cell proliferation, neoangiogenesis
and invasion.
In tumorigenic mice generated by subcutaneous injection of glioma cell lines, overexpres‐
sion of antisense VEGF (C6-VEGF(-/-) mice) significantly suppressed tumor growth, de‐
creased angiogenesis and reduced tumoral edema. Further studies by electron microscope
revealed that tumor-induced hyperpermeability was mediated by formation of vesiculo-va‐
cuolar organelles (VVO), specifically reducing the number of vesicle and caveolae in VVO,
and this effect was partially blocked by antisense VEGF [227].
Recently was evaluated the suitability of folate-PAMAM dendrimer conjugates for efficient
EGFR AON delivery into glioma cells, wherein they release the AON from the FA-PAMAM
to knock down EGFR expression in C6 glioma cells, both in vitro and in vivo. Folic acid was
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coupled to the surface amino groups of G5-PAMAM dendrimer (G5D) through a 1-[3-(dime‐
thylamino)propyl]-3-ethylcarbodiimide bond, and AONs corresponding to rat EGFR were
then complexed with FA-PAMAM. The AON transfection rates mediated by FA-PAMAM
and PAMAM resulting in greater suppression of EGFR expression and glioma cell growth
[228]. In a previous study, was demonstrated that antisense-EGFR transfection inhibited the
growth and transforming phenotype of U87MG cells. In this research, the co-transfection of
U87MG cells with wild-type PTEN and antisense EGFR constructs could inhibit the cellular
growth by 91.7% [229].
Inhibition of PKC-α expression by a synthetic AON inhibits proliferation of C6 glioma cells.
In addition, inhibition of PKC-α expression, has also showed growth inhibition of trans‐
formed U-87 cells transfected with antisense anti-PKC-α oligonucleotide [230]. PKC- α anti‐
sense oligonucleotide treatment in GBM and in A172 GBM cells was accompanied by
reduction in PKC-α levels and the induction of wild-type p53 and insulin-like growth factor-
binding protein-3 (IGFBP3) 24-72 h after treatment. Increased IGFBP3 levels were accompa‐
nied by increased mRNA levels. Recombinant human IGFBP3 induced an apoptotic effect
that was similar to the PKC- α antisense oligonucleotide, and its effect was blocked by IGF-I
[231]. Other potential therapeutic targets are human C-raf kinase and c-Ki-RAS proteins and
signal transduction kinase proteins, involved in the control of proliferation, cellular migra‐
tion and differentiation, and cytoskeletal rearrangements.
In a murine model, was showed the down-regulation of proliferation rate of C6 glioma cells
transfected with antisense AKT2 cDNA construct. Parental C6 cells and C6 cells, transfected
with antisense construct, were implanted through lipofectamine complexes. Dominant-neg‐
ative (DN-AKT2) and antisense AKT2 constructs (AS-AKT2) were transfected into rat C6
glioma cells with elevated endogenous AKT2 expression. AKT2 expression was inhibited in
C6 cells transfected with AS-AKT2 but did not significantly change in cells transfected with
DN-AKT2. The cell migration distance was reduced in cells transfected with DN-AKT2 or
AS-AKT2 compared to the control cells and gelatin zymography showed that the produc‐
tion of MMP2 and MMP9 was inhibited in transfected cells [232]. Edwards et al. targeted the
phosphatidylinositol 3-kinase/protein kinase B (PKB)/Akt and the Ras/MAPK pathway for
their involvement in cell survival and cell proliferation. The glioblastoma cell lines U87MG,
SF-188, and U251MG were transiently transfected with an antisense oligonucleotide target‐
ing ILK (ILKAS) alone or in combination with the Raf-1 inhibitor GW5074 or with the MEK
inhibitor U0126. Glioblastoma cells transfected with ILKAS exhibited reduced levels of ILK
and phosphorylated PKB/Akt on Ser473. These results confirmed that combinations target‐
ing ILK and components of the Ras/MAPK pathway result in synergy and could potentially
be more effective against glioblastoma cancer than monotherapy [233].
During progression of human gliomas, the expression of capillary BM laminins containing
α4 chain switches from the predominant laminin-9 into lanimin-8. Effects of antisense inhib‐
ition of laminin-8 expression in glioma therapy through an in vitro model using human
GBM cell lines M059K and U-87MG co-cultured with normal human brain microvascular
endothelial cells (HBMVEC) have been observed. Laminin-8 and its receptor, integrins α3β1
and α6β1, are important for the functioning of endothelial cell BMs, which play a role in the
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maintenance of the BBB. Laminin-8 plays an important role in glioma cell invasiveness, in
combination with other proteins associated with glioma progression, such as tenascin-C,
MMP-2 and MMP-9. In this study was demonstrated a significant reduction of invasion of
co-cultures through Matrigel and through the use of morpholino oligos against α4 and β1
chains of laminin-8 [234]. The downregulation of laminin α4 chain using AONs inhibits the
motility of human glioma cells was shown. Laminin α4 chain appears to be an important
factor in glioma migration and invasion, both in vitro and in vivo [235].
The antisense modulation of Bcl-2 expression could increase the effectiveness of convention‐
al chemotherapeutic agent. Antisense human bcl-2 cDNA was transfected into human ma‐
lignant glioma cells. The effects of bcl-2 protein down-regulation on glioma cell
morphology, in vitro tumor growth, and tumorigenicity in nude mice, as well as chemosen‐
sitivity to cisplatin, were studied. Expression of antisense bcl-2 cDNA decreased bcl-2 pro‐
tein by more than sixfold. Antisense bcl-2 stable transfectants (AS-bcl-2) showed profound
morphological change, marked retarded cell growth in vitro and significantly increased cy‐
totoxicity of cisplatin [236]. Phase I and II studies are also being done to test G3139 in combi‐
nation with docetaxel in patients with advanced breast cancer, hormone-refractory prostate
cancer, and other solid tumors. By using AONs against the first six codons of the human
Bcl-2 gene transfected into malignant glioma cells (Jon52 and Roc GBM cell lines), has been
demonstrated a decrease in cell growth and an increase in apoptotic death [237]. There is a
link between resistance to chemotherapy in glioblastoma and expression of antiapoptotic
bcl-2 family members, including bcl-XL. Anti-bcl-XL AONs (ISIS 16009, ISIS 16967) in
M059K GBM cell lines have been used and demonstrated a valid correlation between reduc‐
tion of bcl-XL protein expression, induction of intrinsic apoptotic pathway and enhance‐
ment of cytotoxic responses to paclitaxel treatment, resulting in a chemosensitizing effect of
anti-bcl-XL therapy [238].
7. Conclusion
Cerebral gliomas remain essentially resistant to traditional cancer therapy. Radiation thera‐
py is limited to a largely palliative role, and chemotherapy has provided only a modest ben‐
efit in the clinical outcome. Ideally we would analyze tumor tissue in order to confirm
adequate concentrations of our agents; however, the difficulties of accessing brain tumor
samples compared with other tumor samples in systemic cancers make this a difficult task.
This also impedes our validation of biological effects in vivo, a crucial step in the assessment
of new interventions and therapies.
Understanding the genetic bases of gliomas and of the invasive behavior may suggest new
molecular targets to overcome the mechanisms of multi-drug-resistance of the actual thera‐
peutic approaches and to attack at the same time different crucial biological events of glio‐
magenesis. In recent years, basic and preclinical studies have revealed multiple new
mechanisms of gliomagenesis and corresponding targets for treatment. Glioma gene expres‐
sion and its development during gliomagenesis will may help to better understand the role
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of important molecules involved in tumor-safe brain parenchyma relationships. These mole‐
cules, such as ECM proteases, cell adhesion molecules and their related signaling pathways
show an important role in glioma cell migration and invasion and could be selectively attack
to inhibit the glioma invasive rim. Targeted therapies are adopted to disrupt the function of
their targets or deliver toxins to tumor cells expressing the target. However, drugs targeting
single molecules show a limited efficacy, because multiple abnormalities are simultaneously
present in glioma patients. It is clear that the complexity and cross-talk between signal trans‐
duction pathways limits the potential efficacy of targeting a single receptor or molecule. As
a result of a tested preclinical study, clusterin, eukaryotic initiation factor-4E (eIF-4E), integ‐
rins, metalloproteinases and other key molecules (involved in invasion and angiogenesis)
might be possible future interesting molecular targets in glioma therapy. Targeting of multi‐
ple signaling pathways by multitargeted kinase inhibitors or combinations of single-target‐
ed kinase inhibitors may increase treatment efficacies. Parallel to this is the task of
determining the unique molecular and genetic profiles of individual patient tumors so that
the most effective therapies can be selected for those individuals. Targeted agents are likely
to have the greatest potential when used in combination to increase the activity of standard
chemotherapies, broadening the range of pathways inhibited by treatment and/or counter‐
acting mechanisms of resistance. In addition, as for classic cytotoxic agents, an intact BBB
may represent an important impediment limiting the efficacy of targeted therapies.
Nanotechnology provides a unique opportunity to combat cancer on the molecular scale
through careful engineering of nanomedicines to specifically interact with cancer cells and
inhibit cancer cell function. It is also possible to take into neoplastic tissue, novel selective
contrast enhancement molecules to visualize brain tumors and to study in vivo all of their
characteristics, such as cellular proliferation, angiogenesis, necrosis, tumor-safe tissue inter‐
face, and edema. There are significant opportunities to investigate the use of nuclear imag‐
ing techniques such as positron emission tomography (PET) and single-photon emission
computed tomography (SPECT) for development of radiolabeled nanoparticles targeting
cancer. The versatility, sensitivity and tomographic imaging capabilities of these imaging
modalities will provide excellent opportunities for future development of targeted nanopar‐
ticle formulations. The surface of nanoparticles can be modified to achieve targeted delivery
and improved biocompatibility. Compounds may also be encapsulated within the interior
core of nanoparticles for multiple functions. Nanoparticle-based delivery systems could in‐
crease the overcoming of the BBB by the use of drugs with a targeted-cell specificity modali‐
ty. This approach permits the use of a lower dose of drug, a selective drug delivery to target
tumor cells, both into the central core of tumor and into the distal foci of tumor cells within
areas often characterized from integrity of the BBB [239-240]. Considerable effort has been
made toward the research and development of multifunctional nano-particle systems for
cancer targeted imaging and therapy. Theranostic nanomedicine represent an integrated
nanotherapeutic system, which can diagnose, deliver targeted therapy, and monitor the re‐
sponse to therapy. This integration of diagnostic imaging capability with therapeutic inter‐
ventions is critical to addressing the challenges of brain tumor hetereogeneity and
adaptation. As a platform technology, nanomedicine has the advantage of being able to tar‐
get multiple tumor markers and deliver multiple agents simultaneously for synergy in ad‐
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dressing the challenges of cancer hetereogeneity and adaptative resistance. Nanoparticle
drug delivery vehicles have shown the ability to encapsulate a variety of therapeutic agents
such as small molecules (hydrophilic and/or hydrophobic), peptides, protein-based drugs,
and nucleic acids. By encapsulating these molecules inside a nanocarrier, the solubility and
stability of the drugs can be improved, providing an opportunity to reevaluate potential
drugs previously ignored because of poor pharmacokinetics. Encapsulated molecules can be
released from nanocarriers in a controlled manner over time to maintain a drug concentra‐
tion within a therapeutic window or the release can be triggered by some stimulus unique to
the delivery site [241]. The surface of the nanocarrier can be engineered to increase the blood
circulation half-life and influence the bio-distribution, while attachment of targeting ligands
to the surface can result in enhanced uptake by target tissues.
On the basis of the data collected and of the limits of actual standard therapeutic protocol,
we think that targeted therapy represents an interesting approach to modify the biological
development of gliomas, probably trying to modulate crucial pathways of gliomagenesis
during precocious steps of tumor progression and more molecular targets of the same path‐
way or of two different pathways.
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